% Encoding: UTF-8
@COMMENT{BibTeX export based on data in FAU CRIS: https://cris.fau.de/}
@COMMENT{For any questions please write to cris-support@fau.de}
@article{faucris.237821281,
abstract = {Purpose: Second opinions in oncology are becoming increasingly important in an era of more complex treatments and a growing demand for information by patients. Therefore, we analyzed their effects and influencing factors like patients’ motives, subjective extent of information and satisfaction with communications. Methods: This prospective study evaluated second opinions for patients with breast cancer or gynecological malignancy. The patients received a questionnaire before and two months after, which inquired expectations, reasons, and satisfaction with the second opinion and the attending physicians. Results: A total of 164 patients were included and the majority had breast cancer (75.0%). Receiving the second opinion made 89.7% feel better informed, their need for information decreased (from 75.3% to 39.2%, P < 0.0001), and satisfaction with doctor–patient communications increased (from 61.9 to 91.8%, P = 0.0002). There were various reasons for requesting a second opinion, e.g., the extremely stressful situation of a cancer diagnosis, hope for change in the treatment recommendation or dissatisfaction with the initial physicians. Conclusions: Second opinions can lead to significantly greater patient satisfaction, meeting the need for information and leading to better management of patients in the extremely stressful situation of a cancer diagnosis. Doctor–patient communications play a key role.},
author = {Löhberg, Christian and Meyer, Julia and Häberle, Lothar and Hack, Carolin and Jud, Sebastian and Hein, Alexander and Wunderle, Marius and Emons, Julius and Gaß, Paul and Fasching, Peter and Egloffstein, Sainab and Krebs, Jessica and Erim, Yesim and Beckmann, Matthias and Lux, Michael P. and Wasner, Sonja},
doi = {10.1007/s00404-020-05525-2},
faupublication = {yes},
journal = {Archives of Gynecology and Obstetrics},
keywords = {Breast cancer; Doctor–patient communication; Gynecological malignancy; Oncology center; Patient satisfaction; Second opinion},
note = {CRIS-Team Scopus Importer:2020-04-28},
peerreviewed = {Yes},
title = {{Analysis} of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center},
year = {2020}
}
@article{faucris.242202004,
abstract = {Introduction: Oncological second opinions are becoming increasingly important given more complex treatment strategies, simultaneously more patients use complementary and alternative medicine (CAM), and many comprehensive cancer centers initiate integrative medicine programs. The present study focuses on analyzing the effects of a second opinion in relation to attitudes toward CAM. Methods: In this prospective study patients (n = 97) with a diagnosis of breast cancer or gynecological malignancies who had requested a second opinion received a questionnaire before and after the second opinion concerning their attitudes toward CAM. Results: The majority of patients had breast cancer (72.2%, n = 70). Only 6.2% (n = 6) stated that they had been informed about CAM by the doctors who treated them first, 21.6% (n = 21) had received information about it when seeking the second opinion. After the first opinion, 42.3% (n = 41) wanted to try CAM, the same proportion trusted orthodox medicine alone. After the second opinion, 24 patients (24.7%) wanted to try CAM, while 38.1% (n = 37) relied exclusively on orthodox medicine. There was a significant correlation between an increased patients' need for information and interest in CAM (p = 0.02). Conclusions: Today, aspects of CAM still are very often no part of oncological first and second opinions. This might hence lead to discouraging patients to try out CAM and therefore integrative medicine programs in comprehensive cancer centers might be problem-solving.},
author = {Hack, Carolin and Wasner, Sonja and Meyer, Julia and Häberle, Lothar and Jud, Sebastian and Hein, Alexander and Wunderle, Marius and Emons, Julius and Gaß, Paul and Fasching, Peter and Egloffstein, Sainab and Beckmann, Matthias and Lux, Michael P. and Löhberg, Christian},
doi = {10.1159/000508235},
faupublication = {yes},
journal = {Complementary Medicine Research},
keywords = {Breast cancer; Complementary and alternative medicine; Gynecological malignancies; Integrative medicine; Oncological center; Second opinion},
note = {CRIS-Team Scopus Importer:2020-09-04},
peerreviewed = {Yes},
title = {{Analysis} of {Oncological} {Second} {Opinions} in a {Certified} {University} {Breast} and {Gynecological} {Cancer} {Center} in {Relation} to {Complementary} and {Alternative} {Medicine}},
year = {2020}
}
@article{faucris.242201262,
abstract = {Introduction: Oncological second opinions are becoming increasingly important in the era of complex treatments and established certified cancer centers. Oncological guidelines with the highest levels of evidence are available, but these can only be effective to the extent that they are implemented. Therefore, we analyzed the effects of second opinions with regard to their agreement with first opinions and conformity with guidelines. Methods: In 164 patients with a diagnosis of breast cancer or gynecological malignancy who requested a second opinion, the first and second opinions, established at the interdisciplinary tumor conference, and conformity with the guidelines were evaluated. Results: The first opinion was not in agreement with the guidelines in 34.8% (15.2% diagnosis, 12.8% surgical therapy, 13.4% systemic therapy, and 5.5% radiotherapy), and the recommendations were optimized in the second opinion in 56.7% (28.7% diagnosis, 15.9% surgical therapy, 30.5% systemic therapy, and 8.5% radiotherapy). Conclusions: Oncological second opinions showed significant effects and one-third of first opinions were not in conformity with the guidelines. In a significant proportion of cases, the existing treatment plan was changed or supplemented to allow modern and individualized treatment approaches.},
author = {Lux, Michael P. and Wasner, Sonja and Meyer, Julia and Häberle, Lothar and Hack, Carolin and Jud, Sebastian and Hein, Alexander and Wunderle, Marius and Emons, Julius and Gaß, Paul and Fasching, Peter and Egloffstein, Sainab and Krebs, Jessica and Erim, Yesim and Beckmann, Matthias and Löhberg, Christian},
doi = {10.1159/000509127},
faupublication = {yes},
journal = {Breast Care},
note = {CRIS-Team Scopus Importer:2020-09-04},
peerreviewed = {Yes},
title = {{Analysis} of {Oncological} {Second} {Opinions} in a {Certified} {University} {Breast} and {Gynecological} {Cancer} {Center} {Regarding} {Consensus} between the {First} and {Second} {Opinion} and {Conformity} with the {Guidelines}},
year = {2020}
}
@inproceedings{faucris.212705640,
address = {OXFORD},
author = {Häberle, Lothar and Erber, Ramona and Gaß, Paul and Hein, Alexander and Jud, Sebastian and Langemann, Hanna and Rauh, C. and Hack, Caroline and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Beckmann, Matthias and Lux, Michael P. and Fasching, Peter},
booktitle = {ANNALS OF ONCOLOGY},
date = {2018-10-19/2018-10-23},
doi = {10.1093/annonc/mdy270.221},
faupublication = {yes},
note = {CRIS-Team WoS Importer:2019-03-08},
peerreviewed = {unknown},
publisher = {OXFORD UNIV PRESS},
title = {{A} prediction model for pathological complete response after neoadjuvant chemotherapy of {HER2}-negative breast cancer patients},
venue = {Munich},
year = {2018}
}
@article{faucris.204645248,
abstract = {In recent years complementary and alternative medicine (CAM) has increasingly been the focus of international research. Numerous subsidised trials (7903) and systematic reviews (651) have been published, and the evidence is starting to be integrated into treatment guidelines. However, due to insufficient evidence and/or insufficient good quality evidence, this has mostly not translated to practice recommendations in reviews by the Cochrane collaboration gynaecology group. There is nevertheless a not insignificant number of CAM providers and users. The percentage of oncology patients who use CAM varies between 5 and 90 %. Doctors have been identified as the main providers of CAM. Half of gynaecologists offer CAM because of personal conviction or on suggestion from colleagues. This must be viewed in a critical light, since CAM is mostly practiced without appropriate training, often without sufficient evidence for a given method - and where evidence exists, practice guidelines are lacking - and lack of safety or efficacy testing. The combination of patient demand and lucrativeness for doctors/alternative medicine practitioners, both based on supposed effectiveness CAM, often leads to its indiscriminate use with uncertain outcomes and significant cost for patients. On the other hand there is published, positive level I evidence for a number of CAM treatment forms. The aim of this article is therefore to review the available evidence for CAM in gynaecological oncology practice. The continued need for research is highlighted, as is the need to integrate practices supported by good evidence into conventional gynaecological oncology.},
author = {Kalder, M. and Mueller, T. and Fischer, D. and Mueller, A. and Bader, W. and Beckmann, Matthias and Brucker, C. and Hack, Carolin and Hanf, V. and Hasenburg, A. and Hein, Alexander and Jud, Sebastian and Kiechle, M. and Klein, E. and Paepke, D. and Rotmann, A. and Schuetz, F. and Dobos, G. and Voiss, P. and Kuemmel, S.},
doi = {10.1055/s-0042-100208},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
note = {EVALuna2:32999},
pages = {150-155},
peerreviewed = {Yes},
title = {{A} {Review} of {Integrative} {Medicine} in {Gynaecological} {Oncology}},
volume = {76},
year = {2016}
}
@article{faucris.107396784,
abstract = {Pregnancies and breastfeeding are two important protective factors concerning breast cancer risk. Breast volume and breast volume changes might be a breast phenotype that could be monitored during pregnancy and breastfeeding without ionizing radiation or expensive equipment. The aim of the present study was to document changes in breast volume during pregnancy prospectively. In the prospective Clinical Gravidity Association Trial and Evaluation programme, pregnant women were followed up prospectively from gestational week 12 to birth. Three-dimensional breast surface imaging and subsequent volume assessments were performed. Factors influencing breast volume at the end of the pregnancy were assessed using linear regression models. Breast volumes averaged 420 ml at the start of pregnancy and 516 ml at the end of pregnancy. The first, second and third quartiles of the volume increase were 41, 95 and 135 ml, respectively. Breast size increased on average by 96 ml, regardless of the initial breast volume. Breast volume increases during pregnancy, but not all womens' breasts respond to pregnancy in the same way. Breast volume changes during pregnancy are an interesting phenotype that can be easily assessed in further studies to examine breast cancer risk.},
author = {Bayer, Christian M. and Bani, Mayada and Schneider, Michael and Dammer, Ulf and Raabe, Eva and Haeberle, Lothar and Faschingbauer, Florian and Schneeberger, Sabine and Renner, Stefan and Fischer, Dorothea and Schulz-Wendtland, Rüdiger and Fasching, Peter and Beckmann, Matthias and Jud, Sebastian},
doi = {10.1097/CEJ.0b013e3283651ccb},
faupublication = {yes},
journal = {European Journal of Cancer Prevention},
note = {EVALuna2:14487},
pages = {151-7},
peerreviewed = {Yes},
title = {{Assessment} of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective {CGATE} study},
volume = {23},
year = {2014}
}
@article{faucris.261681404,
abstract = {Mammographic density (MD) has consistently been found as one of the strongest breast cancer risk factors. In our study, both qualitative and quantitative density measurements were performed in a hospital-based group of premenopausal women before and after first full-term pregnancy providing an opportunity for direct evaluation of the effects of one pregnancy on MD. Mammograms were obtained from 23 women before and after first full-term pregnancy and from 28 nulliparous controls. MD was determined by a standard qualitative assessment method using the Breast Imaging Reporting and Data System, and a quantitative computer-based threshold method (0-100%). The mean age at mammography before and after pregnancy was 31 and 34 years, respectively, with a mean difference of 40 months between mammographies. The quantitative density assessment showed a significant reduction in relative MD after pregnancy of 12 percentage points (8.6-15.4), compared with 3.1 (0.0-6.2) in the nulliparous control group (P<0.001). A reduction in MD of more than 10% was seen in 52% of the patients, compared with 18% of the controls. The qualitative density assessment confirmed a reduction in MD after pregnancy by one Breast Imaging Reporting and Data System category (P=0.02). This longitudinal study showed that MD can be influenced by one full-term pregnancy. This effect was seen with both quantitative and qualitative assessment methods. It may be hypothesized that breast cancer risk reduction associated with pregnancy is mediated through a direct reduction of MD, and MD assessment might be incorporated in individualizing risk assessment and prevention. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.},
author = {Löhberg, Christian and Heusinger, Katharina and Jud, Sebastian and Häberle, Lothar and Hein, Alexander and Rauh, Claudia and Bani, Mayada and Lux, Michael P. and Schrauder, Michael G. and Bayer, Christian M. and Helbig, Cosima and Grolik, Ronald and Adamietz, Boris and Schulz-Wendtland, Rüdiger and Beckmann, Matthias and Fasching, Peter},
doi = {10.1097/CEJ.0b013e32833ca1f4},
faupublication = {no},
journal = {European Journal of Cancer Prevention},
keywords = {Breast cancer risk; mammographic density; pregnancy},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {405-412},
peerreviewed = {Yes},
title = {{Assessment} of mammographic density before and after first full-term pregnancy},
volume = {19},
year = {2010}
}
@article{faucris.243041623,
abstract = {Background: Mammography can identify calcifications up to 50–100 μm in size as a surrogate parameter for breast cancer or ductal carcinoma in situ (DCIS). Microcalcifications measuring <50 µm are also associated with breast cancer or DCIS and are frequently not detected on mammography, although they can be detected with dark-field imaging. This study examined whether additional breast examination using X-ray dark-field imaging can increase the detection rate of calcifications. Advances in knowledge: (1) evaluation of additional modality of breast imaging; (2) specific evaluation of breast calcifications. Implications for patient care: the addition of X-ray dark-field imaging to conventional mammography could detect additional calcifications. Methods: Talbot–Lau X-ray phase–contrast imaging and X-ray dark-field imaging were used to acquire images of breast specimens. The radiation dosage with the technique is comparable with conventional mammography. Three X-ray gratings with periods of 5–10 µm between the X-ray tube and the flat-panel detector provide three different images in a single sequence: the conventional attenuation image, differential phase image, and dark-field image. The images were read by radiologists. Radiological findings were marked and examined pathologically. The results were described in a descriptive manner. Results: A total of 81 breast specimens were investigated with the two methods; 199 significant structures were processed pathologically, consisting of 123 benign and 76 malignant lesions (DCIS or invasive breast cancer). X-ray dark-field imaging identified 15 additional histologically confirmed carcinoma lesions that were visible but not declared suspicious on digital mammography alone. Another four malignant lesions that were not visible on mammography were exclusively detected with X-ray dark-field imaging. Conclusions: Adding X-ray dark-field imaging to digital mammography increases the detection rate for breast cancer and DCIS associated lesions with micrometer-sized calcifications. The use of X-ray dark-field imaging may be able to provide more accurate and detailed radiological classification of suspicious breast lesions. Adding X-ray dark-field imaging to mammography may be able to increase the detection rate and improve preoperative planning in deciding between mastectomy or breast-conserving therapy, particularly in patients with invasive lobular breast cancer.},
author = {Emons, Julius and Fasching, Peter and Wunderle, Marius and Heindl, Felix and Rieger, Jens and Horn, Florian and Pelzer, Georg and Ritter, André and Weber, Thomas and Radicke, Marcus and Polifka, Iris and Wachter, David and Wenkel, Evelyn and Michel, Thilo and Uder, Michael and Hartmann, Arndt and Anton, Gisela and Beckmann, Matthias and Schulz-Wendtland, Rüdiger and Jud, Sebastian},
doi = {10.1177/1758835920957932},
faupublication = {yes},
journal = {Therapeutic Advances in Medical Oncology},
keywords = {breast cancer; interferometry; mammography; microcalcifications},
note = {CRIS-Team Scopus Importer:2020-09-25},
peerreviewed = {Yes},
title = {{Assessment} of the additional clinical potential of {X}-ray dark-field imaging for breast cancer in a preclinical setup},
volume = {12},
year = {2020}
}
@article{faucris.214903150,
abstract = {PurposeEvidence shows that genetic and non-genetic risk factors for breast cancer (BC) differ relative to the molecular subtype. This analysis aimed to investigate associations between epidemiological risk factors and immunohistochemical subtypes in a cohort of postmenopausal, hormone receptor-positive BC patients.MethodsThe prospective, single-arm, multicenter phase IV PreFace study (Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy) included 3529 postmenopausal patients with hormone receptor-positive early BC. Data on their epidemiological risk factors were obtained from patients' diaries and their medical histories. Data on estrogen receptor, progesterone receptor, and HER2 receptor status were obtained from pathology reports. Patients with incomplete information were excluded. Data were analyzed using conditional inference regression analysis, analysis of variance, and the chi-squared test.ResultsIn a cohort of 3392 patients, the strongest association with the molecular subtypes of BC was found for hormone replacement therapy (HRT) before diagnosis of early BC. The analysis showed that patients who took HRT at diagnosis had luminal A-like BC more often (83.7%) than those who had never taken HRT or had stopped taking it (75.5%). Luminal B-like BC and HER2-positive BC were diagnosed more often in women who had never taken HRT or had stopped taking it (13.3% and 11.2%, respectively) than in women who were taking HRT at diagnosis of BC (8.3% and 8.0%, respectively).ConclusionsThis analysis shows an association between HRT and the distribution of molecular subtypes of BC. However, no associations between other factors (e.g., age at diagnosis, body mass index, smoking status, age at menopause, number of deliveries, age at first delivery, breastfeeding history, or family history) were noted.},
author = {Wunderle, Marius and Pretscher, Jutta and Brucker, Sara Y. and Volz, Bernhard and Hartmann, Arndt and Fießler, Cornelia and Hein, Alexander and Häberle, Lothar and Jud, Sebastian and Lux, Michael P. and Janni, Wolfgang and Löhberg, Christian and Hartkopf, Andreas D. and Walter, Christina B. and Baake, Gerold and Fridman, Alexander and Malter, Wolfram and Wuerstlein, Rachel and Harbeck, Nadia and Hoffmann, Oliver and Kuemmel, Sherko and Martin, Bernhard and Thomssen, Christoph and Graf, Heiko and Wolf, Christopher and Bayer, Christian M. and Hack, Carolin and Almstedt, Katrin and Gaß, Paul and Heindl, Felix and Brodkorb, Tobias F. and Nabieva, Naiba and Lindner, Christoph and Kolberg, Hans-Christian and Krabisch, Petra and Weigel, Michael and Steinfeld-Birg, Dieter and Kohls, Andreas and Brucker, Cosima and Schulz, Volker and Fischer, Gunnar and Pelzer, Volker and Wallwiener, Diethelm and Rack, Brigitte and Fehm, Tanja and Rody, Achim and Maass, Nicolai and Beckmann, Matthias and Fasching, Peter and Rauh, Claudia},
doi = {10.1007/s10549-018-05115-6},
faupublication = {yes},
journal = {Breast Cancer Research and Treatment},
note = {CRIS-Team WoS Importer:2019-03-29},
pages = {453-461},
peerreviewed = {Yes},
title = {{Association} between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer},
volume = {174},
year = {2019}
}
@article{faucris.119841964,
abstract = {Percentage mammographic density (PMD) is a major risk factor for breast cancer (BC). It is strongly associated with body mass index (BMI) and age, which are themselves risk factors for breast cancer. This analysis investigated the association between the number of full-term pregnancies and PMD in different subgroups relative to age and BMI.Patients were identified in the breast cancer database of the University Breast Center for Franconia. A total of 2410 patients were identified, for whom information on parity, age, and BMI, and a mammogram from the time of first diagnosis were available for assessing PMD. Linear regression analyses were conducted to investigate the influence on PMD of the number of full-term pregnancies (FTPs), age, BMI, and interaction terms between them.As in previous studies, age, number of FTPs, and BMI were found to be associated with PMD in the expected direction. However, including the respective interaction terms improved the prediction of PMD even further. Specifically, the association between PMD and the number of FTPs differed in young patients under the age of 45 (mean decrease of 0.37 PMD units per pregnancy) from the association in older age groups (mean decrease between 2.29 and 2.39 PMD units). BMI did not alter the association between PMD and the number of FTPs.The effect of pregnancies on mammographic density does not appear to become apparent before the age of menopause. The mechanism that drives the effect of pregnancies on mammographic density appears to be counter-regulated by other influences on mammographic density in younger patients.},
author = {Hack, Carolin and Emons, Julius and Jud, Sebastian and Heusinger, Katharina and Adler, Werner and Gaß, Paul and Haeberle, Lothar and Heindl, Felix and Hein, Alexander and Schulz-Wendtland, Rüdiger and Uder, Michael and Hartmann, Arndt and Beckmann, Matthias and Fasching, Peter and Pöhls, Uwe G.},
doi = {10.1007/s10549-017-4446-7},
faupublication = {yes},
journal = {Breast Cancer Research and Treatment},
note = {EVALuna2:14710},
pages = {701-708},
peerreviewed = {Yes},
title = {{Association} between mammographic density and pregnancies relative to age and {BMI}: a breast cancer case-only analysis},
volume = {166},
year = {2017}
}
@article{faucris.109073624,
abstract = {As breast cancer (BC) screening identifies many BCs with a good prognosis, which might be overdiagnosed and therefore overtreated, the identification of subgroups with a high risk for aggressive subtypes might be helpful. The aim of this case-case analysis was to investigate the association between epidemiological risk factors and molecular subtypes in a cohort of BC patients. Epidemiological risk factors for 2587 BC patients were obtained using a structured questionnaire and from the patients' charts. The histopathological information (estrogen and progesterone receptor, HER2 and Ki-67) used in the analysis was retrieved from the original pathology reports. Analyses using conditional inference regression trees were carried out on these data. The strongest influence factor on the distribution of the molecular subtypes was age at first diagnosis of BC. An influence of BMI was also identified in patients aged either more than 42 years or 49.6 years or less. Older patients aged more than 49.6 years and perimenopausal women with a BMI of 32.4 kg/m or less were most likely to develop luminal A-like BC. Young patients aged 42 years or less and perimenopausal patients with a BMI more than 32.4 kg/m more often developed triple-negative BC. The study confirmed that age at diagnosis is an important factor influencing the distribution of molecular subtypes. In the perimenopausal group, it may be postulated that BMI plays a critical role in the pathogenesis of BC, defining a subgroup that is more likely to develop triple-negative BC or luminal B-like disease and another group in which there is a more postmenopausal distribution pattern.},
author = {Rauh, Claudia and Gaß, Paul and Heusinger, Katharina and Haeberle, Lothar and Jud, Sebastian and Hein, Alexander and Löhberg, Christian and Lux, Michael P. and Wachter, David and Heimrich, Jutta and Strehl, Johanna D. and Haller, Florian and Hartmann, Arndt and Schulz-Wendtland, Rüdiger and Fießler, Cornelia and Beckmann, Matthias and Fasching, Peter and Pöhls, Uwe G.},
doi = {10.1097/CEJ.0000000000000111},
faupublication = {yes},
journal = {European Journal of Cancer Prevention},
note = {EVALuna2:5482},
pages = {484-90},
peerreviewed = {Yes},
title = {{Association} of molecular subtypes with breast cancer risk factors: a case-only analysis},
volume = {24},
year = {2015}
}
@article{faucris.111708784,
abstract = {The combination of different imaging modalities through the use of fusion devices promises significant diagnostic improvement for breast pathology. The aim of this study was to evaluate image quality and clinical feasibility of a prototype fusion device (fusion prototype) constructed from a standard tomosynthesis mammography unit and a standard 3D ultrasound probe using a new method of breast compression.Imaging was performed on 5 mastectomy specimens from patients with confirmed DCIS or invasive carcinoma (BI-RADS ((TM)) 6). For the preclinical fusion prototype an ABVS system ultrasound probe from an Acuson S2000 was integrated into a MAMMOMAT Inspiration (both Siemens Healthcare Ltd) and, with the aid of a newly developed compression plate, digital mammogram and automated 3D ultrasound images were obtained.The quality of digital mammogram images produced by the fusion prototype was comparable to those produced using conventional compression. The newly developed compression plate did not influence the applied x-ray dose. The method was not more labour intensive or time-consuming than conventional mammography. From the technical perspective, fusion of the two modalities was achievable.In this study, using only a few mastectomy specimens, the fusion of an automated 3D ultrasound machine with a standard mammography unit delivered images of comparable quality to conventional mammography. The device allows simultaneous ultrasound - the second important imaging modality in complementary breast diagnostics - without increasing examination time or requiring additional staff.},
author = {Schulz-Wendtland, Rüdiger and Jud, Sebastian and Fasching, Peter and Hartmann, Arndt and Radicke, Marcus and Rauh, Claudia and Uder, Michael and Wunderle, Marius and Gaß, Paul and Langemann, Hanna and Beckmann, Matthias and Emons, Julius},
doi = {10.1055/s-0043-107034},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
note = {EVALuna2:6849},
pages = {679-685},
peerreviewed = {Yes},
title = {{A} {Standard} {Mammography} {Unit} - {Standard} {3D} {Ultrasound} {Probe} {Fusion} {Prototype}: {First} {Results}},
volume = {77},
year = {2017}
}
@article{faucris.205567447,
abstract = {PURPOSE: BRCA1/2 mutations influence the molecular characteristics and the effects of systemic treatment of breast cancer. This study investigates the impact of germline BRCA1/2 mutations on pathological complete response and prognosis in patients receiving neoadjuvant systemic chemotherapy.
METHODS: Breast cancer patients were tested for a BRCA1/2 mutation in clinical routine work and were treated with anthracycline-based or platinum-based neoadjuvant chemotherapy between 1997 and 2015. These patients were identified in the tumor registry of the Breast Center of the University of Erlangen (Germany). Logistic regression and Cox regression analyses were performed to investigate the associations between BRCA1/2 mutation status, pathological complete response, disease-free survival, and overall survival.
RESULTS: Among 355 patients, 59 had a mutation in BRCA1 or in BRCA2 (16.6%), 43 in BRCA1 (12.1%), and 16 in BRCA2 (4.5%). Pathological complete response defined as "ypT0; ypN0" was observed in 54.3% of BRCA1/2 mutation carriers, but only in 22.6% of non-carriers. The adjusted odds ratio was 2.48 (95% CI 1.26-4.91) for BRCA1/2 carriers versus non-carriers. Patients who achieved a pathological complete response had better disease-free survival and overall survival rates compared with those who did not achieve a pathological complete response, regardless of BRCA1/2 mutation status.
CONCLUSIONS: BRCA1/2 mutation status leads to better responses to neoadjuvant chemotherapy in breast cancer. Pathological complete response is the main predictor of disease-free survival and overall survival, independently of BRCA1/2 mutation status.},
author = {Wunderle, Marius and Gaß, Paul and Häberle, Lothar and Flesch, Vivien M. and Rauh, Claudia and Bani, Mayada and Hack, Carolin and Schrauder, Michael G. and Jud, Sebastian and Emons, Julius and Erber, Ramona and Ekici, Arif Bülent and Hoyer, Juliane and Vasileiou, Georgia and Kraus, Cornelia and Reis, André and Hartmann, Arndt and Lux, Michael P. and Beckmann, Matthias and Fasching, Peter and Hein, Alexander},
doi = {10.1007/s10549-018-4797-8},
faupublication = {yes},
journal = {Breast Cancer Research and Treatment},
note = {EVALuna2:34606},
pages = {85-94},
peerreviewed = {Yes},
title = {{BRCA} mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients},
volume = {171},
year = {2018}
}
@article{faucris.261681907,
abstract = {It has been shown in several studies that antihormonal compounds can offer effective prophylactic treatment to prevent breast cancer. In view of the low participation rates in chemoprevention trials, the purpose of this study was to identify the characteristics of women taking part in a population-based mammography screening program who wished to obtain information about the risk of breast cancer and then participate in the the International Breast Cancer Intervention Study II (IBIS-II) trial, a randomized double-blind controlled chemoprevention trial comparing anastrozole with placebo. A paper-based survey was conducted in a population-based mammography screening program in Germany between 2007 and 2009. All women who met the criteria for the mammography screening program were invited to complete a questionnaire. A total of 2,524 women completed the questionnaire, and 17.7% (n = 446) met the eligibility criteria for the IBIS-II trial after risk assessment. The women who wished to receive further information about chemoprevention were significantly younger (P < 0.01) and had significantly more children (P = 0.03) and significantly more relatives with breast cancer (P < 0.001). There were no significant differences between the participants with regard to body mass index or hormone replacement therapy. Normal mammographic findings at screening were the main reason (42%) for declining to participate in the IBIS-II trial or attend risk counseling. The ultimate rate of recruitment to the IBIS-II trial was very low (three women). Offering chemoprevention to women within a mammography screening unit as part of a paper-based survey resulted in low participation rates for both, the survey and the final participation in the IBIS-II trial. More individualized approaches and communication of breast cancer risk at the time of the risk assessment might be helpful to increase the participation and the understanding of chemopreventive approaches. © 2010 Springer Science+Business Media, LLC.},
author = {Löhberg, Christian and Jud, Sebastian and Häberle, Lothar and Heusinger, Katharina and Dilbat, Gerhard and Hein, Alexander and Rauh, Claudia and Dall, Peter and Rix, Nadine and Heinrich, Sabrina and Buchholz, Stefan and Lex, Benno and Reichler, Barbara and Adamietz, Boris and Schulz-Wendtland, Rüdiger and Beckmann, Matthias and Fasching, Peter},
doi = {10.1007/s10549-010-0845-8},
faupublication = {yes},
journal = {Breast Cancer Research and Treatment},
keywords = {Breast cancer risk; Chemoprevention trial; IBIS-II; Mammography screening; Patient recruitment},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {101-110},
peerreviewed = {Yes},
title = {{Breast} cancer risk assessment in a mammography screening program and participation in the {IBIS}-{II} chemoprevention trial},
volume = {121},
year = {2010}
}
@article{faucris.261675368,
abstract = {Several advancements over the last decade have triggered the developments in the field of breast cancer risk research. One of them is the availability of the human genome sequence along with cheap genotyping possibilities. Another is the globalization of research, which has led to the growth of research collaboration into large international consortia that facilitate the pooling of clinical and genotype data of hundreds of thousands of patients and healthy control individuals. This review concerns with the recent developments in breast cancer risk research and focuses on the discovery of new genetic breast cancer risk factors and their meaning in the context of established non-genetic risk factors. Finally the clinical application is highly dependent on the accuracy of breast cancer risk prediction models, not only for all breast cancer patients, but also for molecular subtypes, preferably for those which are associated with an unfavorable prognosis. Recently risk prediction incorporates all possible risk factors, which include epidemiological risk factors, mammographic density and genetic risk factors. © Georg Thieme Verlag KG Stuttgart• New York•.},
author = {Fasching, Peter and Ekici, Arif Bülent and Wachter, David Lukas and Hein, Alexander and Bayer, Christian M. and Häberle, Lothar and Löhberg, Christian and Schneider, Michael and Jud, Sebastian and Heusinger, K. and Rübner, Matthias and Rauh, Claudia and Bani, Mayada and Lux, Michael P. and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Beckmann, Matthias},
doi = {10.1055/s-0033-1360178},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
keywords = {BRCA; breast cancer risk; gene-environment interaction; genetic risk factors; prediction models},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {1228-1235},
peerreviewed = {Yes},
title = {{Breast} cancer risk - {From} genetics to molecular understanding of pathogenesis},
volume = {73},
year = {2013}
}
@article{faucris.261680902,
abstract = {The information available about breast cancer risk factors has increased dramatically during the last 10 years. In particular, studies of low-penetrance genes and mammographic density have improved our understanding of breast cancer risk. In addition, initial steps have been taken in investigating interactions between genes and environmental factors. This review concerns with actual data on this topic. Several genome-wide association studies (GWASs) with a casecontrol design, as well as large-scale validation studies, have identified and validated more than a dozen single nucleotide polymorphisms (SNPs) associated with breast cancer risk. They are located not only in or close to genes known to be involved in cancer pathogenesis, but also in genes not previously associated with breast cancer pathogenesis, or may even not be related to any genes. SNPs have also been identified that alter the lifetime risk in BRCA mutation carriers. With regard to nongenetic risk factors, studies of postmenopausal hormone replacement therapy (HRT) have revealed important information on how to weigh up the risks and benefits of HRT. Mammographic density (MD) has become an accepted and important breast cancer risk factor. Lifestyle and nutritional considerations have become an integral part of most studies of breast cancer risk, and some improvements have been made in this field as well. More than 10 years after the publication of the first breast cancer prevention studies with tamoxifen, other substances such as raloxifene and aromatase inhibitors have been investigated and have also been shown to have preventive potential. Finally, mammographic screening systems have been implemented in most Western countries during the last decade. These may be developed further by including more individualized methods of predicting the patients breast cancer risk. © Georg Thieme Verlag KG Stuttgart - New York.},
author = {Fasching, Peter and Ekici, Arif Bülent and Adamietz, B. R. and Wachter, David Lukas and Hein, Alexander and Bayer, Christian M. and Häberle, Lothar and Löhberg, Christian and Jud, Sebastian and Heusinger, K. and Rübner, Matthias and Rauh, Claudia and Bani, Mayada and Lux, Michael P. and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Beckmann, Matthias},
doi = {10.1055/s-0031-1280437},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
keywords = {BRCA (breast cancer antigen); breast; breast feeding; CAM (Complementary and Alternative medicine); cancer registry; estrogen receptor},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {1056-1066},
peerreviewed = {Yes},
title = {{Breast} cancer risk - {Genes}, environment and clinics {Mammakarzinomrisiko} - {Gene}, {Umwelt} und {Klinik}},
volume = {71},
year = {2011}
}
@article{faucris.241258806,
abstract = {BACKGROUND: BRCA1/2 deleterious variants account for most of the hereditary breast and ovarian cancer cases. Prediction models and guidelines for the assessment of genetic risk rely heavily on criteria with high variability such as family cancer history. Here we investigated the efficacy of MRI (magnetic resonance imaging) texture features as a predictor for BRCA mutation status. METHODS: A total of 41 female breast cancer individuals at high genetic risk, sixteen with a BRCA1/2 pathogenic variant and twenty five controls were included. From each MRI 4225 computer-extracted voxels were analyzed. Non-imaging features including clinical, family cancer history variables and triple negative receptor status (TNBC) were complementarily used. Lasso-principal component regression (L-PCR) analysis was implemented to compare the predictive performance, assessed as area under the curve (AUC), when imaging features were used, and lasso logistic regression or conventional logistic regression for the remaining analyses. RESULTS: Lasso-selected imaging principal components showed the highest predictive value (AUC 0.86), surpassing family cancer history. Clinical variables comprising age at disease onset and bilateral breast cancer yielded a relatively poor AUC (~ 0.56). Combination of imaging with the non-imaging variables led to an improvement of predictive performance in all analyses, with TNBC along with the imaging components yielding the highest AUC (0.94). Replacing family history variables with imaging components yielded an improvement of classification performance of ~ 4%, suggesting that imaging compensates the predictive information arising from family cancer structure. CONCLUSIONS: The L-PCR model uncovered evidence for the utility of MRI texture features in distinguishing between BRCA1/2 positive and negative high-risk breast cancer individuals, which may suggest value to diagnostic routine. Integration of computer-extracted texture analysis from MRI modalities in prediction models and inclusion criteria might play a role in reducing false positives or missed cases especially when established risk variables such as family history are missing.},
author = {Vasileiou, Georgia and Costa, Maria J. and Long, Christopher and Wetzler, Iris and Hoyer, Juliane and Kraus, Cornelia and Popp, Bernt and Emons, Julius and Wunderle, Marius and Wenkel, Evelyn and Uder, Michael and Beckmann, Matthias and Jud, Sebastian and Fasching, Peter and Reis, André and Hammon, Matthias and Cavallaro, Alexander Josef},
doi = {10.1186/s12880-020-00483-2},
faupublication = {yes},
journal = {BMC Medical Imaging},
keywords = {BRCA1/2; Breast cancer; HBOC; L-PCR; MRI; Texture analysis},
note = {CRIS-Team Scopus Importer:2020-08-07},
pages = {86-},
peerreviewed = {unknown},
title = {{Breast} {MRI} texture analysis for prediction of {BRCA}-associated genetic risk},
volume = {20},
year = {2020}
}
@article{faucris.261678386,
abstract = {Introduction: Although mammographic density is an established risk factor for breast cancer, its use is limited in clinical practice because of a lack of automated and standardized measurement methods. The aims of this study were to evaluate a variety of automated texture features in mammograms as risk factors for breast cancer and to compare them with the percentage mammographic density (PMD) by using a case-control study design.Methods: A case-control study including 864 cases and 418 controls was analyzed automatically. Four hundred seventy features were explored as possible risk factors for breast cancer. These included statistical features, moment-based features, spectral-energy features, and form-based features. An elaborate variable selection process using logistic regression analyses was performed to identify those features that were associated with case-control status. In addition, PMD was assessed and included in the regression model.Results: Of the 470 image-analysis features explored, 46 remained in the final logistic regression model. An area under the curve of 0.79, with an odds ratio per standard deviation change of 2.88 (95% CI, 2.28 to 3.65), was obtained with validation data. Adding the PMD did not improve the final model.Conclusions: Using texture features to predict the risk of breast cancer appears feasible. PMD did not show any additional value in this study. With regard to the features assessed, most of the analysis tools appeared to reflect mammographic density, although some features did not correlate with PMD. It remains to be investigated in larger case-control studies whether these features can contribute to increased prediction accuracy. © 2012 Fasching et al.; licensee BioMed Central Ltd.},
author = {Häberle, Lothar and Wagner, Florian and Fasching, Peter and Jud, Sebastian and Heusinger, Katharina and Löhberg, Christian and Hein, Alexander and Bayer, Christian M. and Hack, Carolin and Lux, Michael P. and Binder, Katja and Elter, Matthias and Muenzenmayer, Christian and Schulz-Wendtland, Rüdiger and Meier-Meitinger, Martina and Adamietz, Boris R. and Uder, Michael and Beckmann, Matthias and Wittenberg, Thomas},
doi = {10.1186/bcr3163},
faupublication = {no},
journal = {Breast Cancer Research},
note = {CRIS-Team Scopus Importer:2021-07-19},
peerreviewed = {Yes},
title = {{Characterizing} mammographic images by using generic texture features},
volume = {14},
year = {2012}
}
@article{faucris.261678638,
abstract = {Introduction: MicroRNAs (miRNAs, miRs) are a class of small, non-coding RNA molecules with relevance as regulators of gene expression thereby affecting crucial processes in cancer development. MiRNAs offer great potential as biomarkers for cancer detection due to their remarkable stability in blood and their characteristic expression in many different diseases. We investigated whether microarray-based miRNA profiling on whole blood could discriminate between early stage breast cancer patients and healthy controls. Methods: We performed microarray-based miRNA profiling on whole blood of 48 early stage breast cancer patients at diagnosis along with 57 healthy individuals as controls. This was followed by a real-time semi-quantitative Polymerase Chain Reaction (RT-qPCR) validation in a separate cohort of 24 early stage breast cancer patients from a breast cancer screening unit and 24 age matched controls using two differentially expressed miRNAs (miR-202, miR-718). Results: Using the significance level of p<0.05, we found that 59 miRNAs were differentially expressed in whole blood of early stage breast cancer patients compared to healthy controls. 13 significantly up-regulated miRNAs and 46 significantly down-regulated miRNAs in our microarray panel of 1100 miRNAs and miRNA star sequences could be detected. A set of 240 miRNAs that was evaluated by radial basis function kernel support vector machines and 10-fold cross validation yielded a specificity of 78.8%, and a sensitivity of 92.5%, as well as an accuracy of 85.6%. Two miRNAs were validated by RT-qPCR in an independent cohort. The relative fold changes of the RT-qPCR validation were in line with the microarray data for both miRNAs, and statistically significant differences in miRNA-expression were found for miR-202. Conclusions: MiRNA profiling in whole blood has potential as a novel method for early stage breast cancer detection, but there are still challenges that need to be addressed to establish these new biomarkers in clinical use. © 2012 Schrauder et al.},
author = {Schrauder, Michael G. and Strick, Reiner and Schulz-Wendtland, Rüdiger and Strissel, Pamela and Kahmann, Laura and Loehberg, Christian R. and Lux, Michael P. and Jud, Sebastian and Hartmann, Arndt and Hein, Alexander and Bayer, Christian M. and Bani, Mayada and Richter, Swetlana and Adamietz, Boris R. and Wenkel, Evelyn and Rauh, Claudia and Beckmann, Matthias and Fasching, Peter},
doi = {10.1371/journal.pone.0029770},
faupublication = {no},
journal = {PLoS ONE},
month = {Jan},
note = {CRIS-Team Scopus Importer:2021-07-19},
peerreviewed = {Yes},
title = {{Circulating} micro-{RNAs} as potential blood-based markers for early stage breast cancer detection},
volume = {7},
year = {2012}
}
@article{faucris.109751664,
abstract = {Introduction: This study aimed to compare the accuracy of sonography versus digital breast tomosynthesis to locate intramammary marker clips placed under ultrasound guidance. Patients and Methods: Fifty patients with suspicion of breast cancer (lesion diameter less than 2 cm [cT1]) had ultrasound-guided core needle biopsy with placement of a marker clip in the center of the tumor. Intramammary marker clips were subsequently located with both sonography and digital breast tomosynthesis. Results: Sonography detected no dislocation of intrammammary marker clips in 42 of 50 patients (84 %); dislocation was reported in 8 patients (16 %) with a maximum dislocation of 7 mm along the x-, y- or z-axis. Digital breast tomosynthesis showed accurate placement without dislocation of the intramammary marker clip in 48 patients (96 %); 2 patients (4 %) had a maximum clip dislocation of 3 mm along the x-, y- or z-axis (p < 0.05). Conclusion: The use of digital breast tomosynthesis could improve the accuracy when locating intramammary marker clips compared to sonography and could, in future, be used to complement or even completely replace sonography.},
author = {Schulz-Wendtland, Rüdiger and Dankerl, Peter and Dilbat, G. and Bani, Mayada and Fasching, Peter and Heusinger, K. and Lux, Michael P. and Löhberg, Christian and Jud, Sebastian and Rauh, C. and Bayer, C. M. and Beckmann, Matthias and Wachter, David and Uder, Michael and Meier-Meitinger, M. and Brehm, Barbara},
doi = {10.1055/s-0034-1396164},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
note = {EVALuna2:6724},
pages = {72-76},
peerreviewed = {Yes},
title = {{Comparison} of {Sonography} versus {Digital} {Breast} {Tomosynthesis} to {Locate} {Intramammary} {Marker} {Clips}},
volume = {75},
year = {2015}
}
@article{faucris.111896004,
abstract = {As breast cancer survivors are benefiting increasingly from advanced forms of therapy, the side effects of locoregional treatment in the adjuvant setting are becoming more and more important. This article presents a new method of assessing the spatial distribution of paresthesia in breast cancer survivors after different locoregional treatments.A structured questionnaire assessing paresthesia, with body pictograms for marking paresthesia areas, was completed by 343 breast cancer survivors. The image information was digitized, generating gray-scale summation images with numbers from 0, indicating black (100 % of the patients had paresthesia), to 255, indicating white (none had paresthesia). The resulting map visualization showed the locations of paresthesia on body pictograms. The group included patients who had undergone breast-conserving surgery (BCS) and mastectomy, and also patients who had received percutaneous and interstitial radiation.A total of 56.5 % of the patients stated that they had paresthesia. The paresthesia areas were distributed within the range suggested by clinical experience. Most patients stated that they had paresthesia in the upper outer quadrant and axilla. Patients who had undergone mastectomy or percutaneous radiotherapy appeared to have more paresthesia on some areas of the body surface. Patients who had undergone mastectomy indicated larger areas of paresthesia than those with BCS-4,066 pixels (px) vs. 2,275 px. Radiotherapy did not appear to influence the spatial distribution of paresthesia.Paresthesia is a common symptom after breast cancer treatment. This paper describes a new method of assessing this side effect to improve and individualize treatment for it in the future.},
author = {Jud, Sebastian and Hatko, Reinhard and Maihoefner, Christian and Bani, Mayada and Schrauder, Michael G. and Lux, Michael P. and Beckmann, Matthias and Bani, Gassan and Eder, Irina and Fasching, Peter and Löhberg, Christian and Rauh, Claudia and Hein, Alexander},
doi = {10.1007/s00404-014-3164-1},
faupublication = {yes},
journal = {Archives of Gynecology and Obstetrics},
note = {EVALuna2:17450},
pages = {135-41},
peerreviewed = {Yes},
title = {{Comprehensive} visualization of paresthesia in breast cancer survivors},
volume = {290},
year = {2014}
}
@article{faucris.261060603,
abstract = {A correction to this paper has been published: https://doi.org/10.1007/s00404-021-06112-9.},
author = {Jud, Sebastian and Cupisti, Susanne and Frobenius, Wolfgang and Winkler, Andrea and Schultheis, Franziska and Antoniadis, Sophia and Beckmann, Matthias and Heindl, Felix},
doi = {10.1007/s00404-021-06112-9},
faupublication = {yes},
journal = {Archives of Gynecology and Obstetrics},
note = {CRIS-Team Scopus Importer:2021-07-02},
peerreviewed = {No},
title = {{Correction} to: {Introducing} multiple-choice questions to promote learning for medical students: effect on exam performance in obstetrics and gynecology ({Archives} of {Gynecology} and {Obstetrics}, (2020), 302, 6, (1401-1406), 10.1007/s00404-020-05758-1)},
year = {2021}
}
@article{faucris.122363824,
abstract = {Percentage mammographic breast density (PMD) is one of the most important risk factors for breast cancer (BC). Calcium, vitamin D, bisphosphonates, and denosumab have been considered and partly confirmed as factors potentially influencing the risk of BC. This retrospective observational study investigated the association between serum calcium level and PMD. A total of 982 BC patients identified in the research database at the University Breast Center for Franconia with unilateral BC, calcium and albumin values, and mammogram at the time of first diagnosis were included. PMD was assessed, using a semiautomated method by two readers. Linear regression analyses were conducted to investigate the impact on PMD of the parameters of serum calcium level adjusted for albumin level, and well-known clinical predictors such as age, body mass index (BMI), menopausal status and confounder for serum calcium like season in which the BC was diagnosed. Increased calcium levels were associated with reduced PMD (P = 0.024). Furthermore, PMD was inversely associated with BMI (P < 0.001) and age (P < 0.001). There was also an association between PMD and menopausal status (P < 0.001). The goodness-of-fit of the regression model was moderate. This is the first study assessing the association between serum calcium level and PMD. An inverse association with adjusted serum calcium levels was observed. These findings add to previously published data relating to vitamin D, bisphosphonates, denosumab, and the RANK/RANKL signaling pathway in breast cancer risk and prevention.},
author = {Hack, Carolin and Stoll, Martin and Jud, Sebastian and Heusinger, Katharina and Adler, Werner and Haeberle, Lothar and Ganslandt, Thomas and Heindl, Felix and Schulz-Wendtland, Rüdiger and Uder, Michael and Beckmann, Matthias and Fasching, Peter and Bayer, Christian M. and Cavallaro, Alexander Josef},
doi = {10.1002/cam4.1066},
faupublication = {yes},
journal = {Cancer Medicine},
note = {EVALuna2:175},
pages = {1473-1481},
peerreviewed = {Yes},
title = {{Correlation} of mammographic density and serum calcium levels in patients with primary breast cancer},
volume = {6},
year = {2017}
}
@article{faucris.214172382,
abstract = {Background: The usefulness of clinical breast examination (CBE) in general and in breast cancer screening programs has been a matter of debate. This study investigated whether adding vision-impaired medical tactile examiners (MTEs) improves the predictiveness of CBE for suspicious lesions and analyzed the feasibility and acceptability of this approach. Methods: The prospective study included 104 patients. Physicians and MTEs performed CBEs, and mammography and ultrasound results were used as the gold standard. Sensitivity and specificity were calculated and logistic regression models were used to compare the predictive value of CBE by physicians alone, MTEs alone, and physicians and MTEs combined. Results: For CBEs by physicians alone, MTEs alone, and both combined, sensitivity was 71, 82, and 89% and specificity was 55, 45, and 35%, respectively. Using adjusted logistic regression models, the validated areas under the curve were 0.685, 0.692, and 0.710 (median bootstrapped p value (DeLong) = 0.381). Conclusion: The predictive value for a suspicious breast lesion in CBEs performed by MTEs in patients without prior surgery was similar to that of physician-conducted CBEs. Including MTEs in the CBE procedure in breast units thus appears feasible and could be a way of utilizing their skills. (c) 2019 S. Karger AG, Basel},
author = {Lux, Michael P. and Emons, Julius and Bani, Mayada and Wunderle, Marius and Sell, Charlotte and Preuss, Caroline and Rauh, Claudia and Jud, Sebastian and Heindl, Felix and Langemann, Hanna and Geyer, Thomas and Brandl, Anna-Lisa and Hack, Carolin and Adler, Werner and Schulz-Wendtland, Rüdiger and Beckmann, Matthias and Fasching, Peter and Gaß, Paul},
doi = {10.1159/000495883},
faupublication = {yes},
journal = {Breast Care},
month = {Jan},
note = {CRIS-Team WoS Importer:2019-03-22},
pages = {41-47},
peerreviewed = {Yes},
title = {{Diagnostic} {Accuracy} of {Breast} {Medical} {Tactile} {Examiners} ({MTEs}): {A} {Prospective} {Pilot} {Study}},
volume = {14},
year = {2019}
}
@article{faucris.247777801,
abstract = {Background: Risk factors for ipsilateral breast cancer tumor recurrence (IBTR) are well established and include grading, nodal status, and receptor status. Little is known about the influence of the local distance between the primary tumor and recurrences on changes in tumor characteristics and prognosis. Methods: In a retrospective setting, we analyzed primary breast cancers and their recurrences. Localizations of primary and recurrent breast cancer were recorded to calculate the relative distance in pixels. Analysis was performed regarding tumor characteristics, relative distance between both, and their impact on breast cancer prognosis. Results: In a cohort of 142 patients with ipsilateral recurrence, no statistically significant difference could be shown in the change in tumor characteristics depending on distance. Progesterone receptor (PR) and estrogene receptor (ER) status changed in 22.7% and 14.9% of cases, respectively. human epidermal growth factor receptor 2 (ERBB2, HER2) status changed in 18.3% of cases. Survival was in accordance with the literature, with luminal-A-like tumors as best and triple negative breast cancers (TNBC) as worst prognosis. With a threshold of 162 pixels, the survival was significantly better in the group with shorter distance. Conclusion: Change in tumor characteristics from primary breast cancer to recurrence occurs more often in PR than ER. In contrast to other work, in this dataset, recurrences with a larger distance to the primary tumor had a worse prognosis in univariate analysis. A Cox model might indicate the possibility that this influence is independent of other risk factors.},
author = {Jud, Sebastian and Hatko, Reinhard and Emons, Julius and Lauterbach, Bianca and Hack, Carolin and Preuss, Caroline and Adler, Werner and Beckmann, Matthias and Heindl, Felix},
doi = {10.3390/jcm9124033},
faupublication = {yes},
journal = {Journal of Clinical Medicine},
note = {CRIS-Team WoS Importer:2021-01-15},
peerreviewed = {Yes},
title = {{Discordance} between {Primary} {Breast} {Cancer} and {Ipsilateral} {Breast} {Cancer} {Tumor} {Recurrence} as a {Function} of {Distance}},
volume = {9},
year = {2020}
}
@article{faucris.261681655,
abstract = {The rapid growth in medical documentation seen in recent decades has affected gynaecologic oncology as well. Particularly for malignant disorders the need for longitudinal and horizontal documentation, centralisation, guideline conformity, and quality management requires dealing with huge stores of data, often in different systems together (mammography screening, internal patient files, DMP, BQS/AQUA, studies, etc). Thanks in part to these redundancies, the mass of data can take on gigantic proportions. Some relief might be found from increased digitalisation, standardisation, and centralisation urged in the new German National Cancer Plan, mainly with respect to repeat data. © 2010 Springer-Verlag.},
author = {Beckmann, K. and Jud, Sebastian and Hein, Alexander and Heusinger, K. and Bayer, Christian M. and Schwenk, M. and Häberle, Lothar and Beckmann, Matthias},
doi = {10.1007/s00129-009-2503-y},
faupublication = {no},
journal = {Gynäkologe},
keywords = {Cancer registers; German National Cancer Plan; Quality management; Therapy guidelines},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {400-410},
peerreviewed = {Yes},
title = {{Documentation} in {Gynaecologic} {Oncology}: {Conflicts} between quality management, science, efficacy, and liability {Dokumentation} in der gynäkologischen {Onkologie}: {Im} {Spannungsfeld} zwischen {Qualitätssicherung} und {Wissenschaft}, {Ergonomie} und {Rechtssicherheit}},
volume = {43},
year = {2010}
}
@article{faucris.279022511,
abstract = {Background Endometrial cancer (EC) is the fifth most common female malignancy and the most common pelvic malignancy. Effective strategies for early detection, prevention, and genetic assessment are discussed in this article. Aim To review the literature on epidemiology, risk factors, and genetics. Materials and Methods This article is based on the current recommendations of the German Society of Obstetrics and Gynecology for the diagnosis and treatment of women with EC. The current literature was summarized based on expert knowledge. Systematic searches in the Medline database and in Cochrane Reviews were performed. The quality of the evidence was rated according to the 2011 Oxford classification. Recommendations and statements were formulated by a representative group using structured consensus methods. Results In Germany, 2.7% of cancer-specific deaths are due to EC. The incidence of EC increases with age and the disease is most often diagnosed in the age group of 75- to 79-year-old women. The lifetime risk of EC is 1.9%. Risk-modulating factors of EC include long-term use of estrogens, progestogen therapy, oral contraceptives, high body mass index, and impaired glucose metabolism. In addition, physical activity and dietary aspects, such as the amount of fat and red meat consumed, as well as soja foods, dietary fibers, vitamins, and specific beverages such as tea and coffee, play an important etiological role. EC also has a genetic component. Immunohistochemical and/or molecular screening is warranted for all patients with EC and has a significant impact on the genetic counselling of affected families as well as on treatment decisions.},
author = {Tempfer, Clemens and Steinke-Lange, Verena and Aretz, Stefan and Schmutzler, Rita and Ortmann, Olaf and Roemer, Thomas and Hanf, Volker and Widhalm, Simone and Reents, Nicola and Jud, Sebastian and Kommoss, Stefan and Nothacker, Monika and Bloedt, Susanne},
doi = {10.1007/s00129-022-04956-z},
faupublication = {yes},
journal = {Die Gynäkologie},
note = {CRIS-Team WoS Importer:2022-07-29},
pages = {470-480},
peerreviewed = {Yes},
title = {{Epidemiology}, risk factors, and genetics of endometrial cancer},
volume = {55},
year = {2022}
}
@article{faucris.123773364,
abstract = {Introduction The placement of intramammary marker clips has proven to be helpful for tumor localization in patients undergoing neoadjuvant chemotherapy and breast-conserving surgery. The purpose of our study was to investigate the feasibility of using a clip marker system for breast cancer localization and its influence on the imaging assessment of treatment responses after neoadjuvant chemotherapy. Patients and Methods Between March and June 2015, a total of 25 patients (n = 25), with a suspicion of invasive breast cancer with diameters of at least 2 cm (cT2), underwent preoperative sonographically guided core needle biopsy using a single-use breast biopsy system (HistoCore(TM)) and intramammary clip marking using a directly adapted clip system based on the established O-Twist Marker(TM), before their scheduled preoperative neoadjuvant chemotherapy. Localization of the intramammary marker clip was controlled by sonography and digital breast tomosynthesis. Results Sonography detected no dislocation of intrammammary marker clips in 20 of 25 patients (80 %), while digital breast tomosynthesis showed accurate placement without dislocation in 24 patients (96 %) (p < 0.05). There was no evidence of significant clip migration during preoperative follow-up imaging after neoadjuvant chemotherapy. No complication related to the clip marking was noted and there was no difficulty in evaluating the treatment response to neoadjuvant chemotherapy. Among the breast-conserving surgeries performed, no cases were identified in which intraoperative loss of the marker clip had occurred. Conclusion Our study underscores the importance of intramammary marking clip systems before neoadjuvant chemotherapy. Placement of marker clips is advised to facilitate accurate tumor bed localization. With regard to digital breast tomosynthesis, its development continues to improve the quality of diagnostics and the therapy of breast cancer particularly for small breast cancer tumors or in neoadjuvant chemotherapy setting.},
author = {Schulz-Wendtland, Rüdiger and Dankerl, P. and Bani, Mayada and Fasching, Peter and Heusinger, K. and Lux, Michael P. and Jud, Sebastian and Rauh, C. and Bayer, C. M. and Schrauder, M. G. and Beckmann, Matthias and Uder, M. and Brehm, Barbara and Löhberg, Christian},
doi = {10.1055/s-0042-124191},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
note = {EVALuna2:14620},
pages = {169-175},
peerreviewed = {Yes},
title = {{Evaluation} of a {Marker} {Clip} {System} in {Sonographically} {Guided} {Core} {Needle} {Biopsy} for {Breast} {Cancer} {Localization} {Before} and {After} {Neoadjuvant} {Chemotherapy}},
volume = {77},
year = {2017}
}
@article{faucris.282837634,
abstract = {BACKGROUND/AIM: Smaller, earlier-stage breast tumors are being found in breast cancer screening, and neoadjuvant chemotherapy is the gold standard when chemotherapy is indicated. Precise marking and localization of the tumor are thus becoming increasingly important. Wire-free localization techniques are under investigation in order to reduce presurgical radiography, pain, the risk of wire dislocation, and allow scheduling flexibility for patients and surgery departments. PATIENTS AND METHODS: This single-center observational study from June 2020 to October 2021 included 15 patients with mammographically or sonographically detected nonpalpable breast lesions. Radiofrequency identification (RFID) tags were placed preoperatively under ultrasound or radiologic guidance to localize lesions for planned surgery. All patients underwent breast conservation surgery, including one bilateral and one targeted axillary dissection. RESULTS: Histology identified two benign and 13 malignant lesions, including three ductal carcinomas in situ and 11 invasive breast cancers. Placement, control radiography, and handling of the RFID tag were feasible in everyday routine for different radiologists and surgeons and managed cost-effectively. All of the RFID tags were found in the specimen radiographs. CONCLUSION: The feasibility and cost-effectiveness of this non-wire localization method were demonstrated in this rather small cohort of patients. Further studies including larger numbers of patients are needed to confirm the method's accuracy.},
author = {Heindl, Felix and Schulz-Wendtland, Rüdiger and Jud, Sebastian and Erber, Ramona and Hack, Carolin and Preuss, Caroline and Behrens, Annika and Pöschke, Patrik and Emons, Julius},
doi = {10.21873/invivo.12965},
faupublication = {yes},
journal = {In Vivo},
keywords = {Breast cancer; localization; RFID; surgery},
note = {CRIS-Team Scopus Importer:2022-10-07},
pages = {2342-2349},
peerreviewed = {Yes},
title = {{Evaluation} of a {Wireless} {Localization} {System} for {Nonpalpable} {Breast} {Lesions} - {Feasibility} and {Cost}-effectiveness in {Everyday} {Clinical} {Routine}},
volume = {36},
year = {2022}
}
@article{faucris.290415282,
abstract = {Introduction: A newly adapted clip system for intramammary marking during ultrasound-guided core needle biopsy for suspicion of breast cancer is described and evaluated here. Material and Method: Fifty patients with suspicion of breast cancer (cT2) had ultrasound-guided core needle biopsy using a newly adapted clip marker system (HistoCore™ and O-Twist Marker™). Subsequently, ultrasound follow-up and tomosynthesis scans were done to determine the location of the marker clips. Results: No dislocation of the marker clip was detected on ultrasound in 45 of 50 patients (90%), and 5 patients (10%) had a maximum dislocation of 5 mm along the x-, y- or z-axis. Tomosynthesis scans demonstrated precise placement without dislocation of the clip markers in 48 patients (96%); 2 patients (4%) had a maximum dislocation of 3 mm along the x-, y- or z-axis. Conclusion: The newly developed clip marker system, a combination of a single-use breast biopsy needle and a precise, length-adapted intramammary marker clip, represents a further improvement in oncological therapy. This is of particular importance for patients requiring subsequent neoadjuvant chemotherapy, as in cases with complete tumour remission, there is no target point for preoperative, ultrasound-guided wire marking. © Georg Thieme Verlag KG Stuttgart New York.},
author = {Schulz-Wendtland, Rüdiger and Dankerl, Peter and Dilbat, G. and Bani, Mayada and Fasching, Peter and Heusinger, K. and Lux, Michael P. and Löhberg, Christian and Jud, Sebastian and Rauh, Claudia and Bayer, Christian M. and Beckmann, Matthias and Uder, Michael and Meier-Meitinger, Martina and Brehm, Barbara},
doi = {10.1055/s-0033-1351086},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
keywords = {biopsy; breast; breast cancer; ultrasound},
note = {CRIS-Team Scopus Importer:2023-03-08},
pages = {1135-1138},
peerreviewed = {Yes},
title = {{Evaluation} of newly adapted clip marker system in ultrasound-guided core needle biopsy for suspicion of breast cancer},
volume = {73},
year = {2013}
}
@article{faucris.123845524,
abstract = {The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL).Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET 2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was clinical response rate as assessed by mammogram readings. The study was terminated prematurely due to insufficient recruitment. We report here on an exploratory analysis of this data.Central assessment of tumor sizes during the treatment period was available for 131 patients (66 LET, 65 LET + ZOL). Clinical responses (complete or partial) were seen in 54.5% (95% CI: 41.8-66.9) of the patients in the LET arm and 69.2% (95% CI: 56.6-80.1) of those in the LET + ZOL arm (P = 0.106). A multivariate model showed an OR of 1.72 (95% CI: 0.83-3.59) for the experimental arm.No increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant treatment regimen with LET. However a trend towards a better reponse in the LET + ZOL arm could be observed. This trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy, and it may support the evidence for a direct antitumor action of zoledronic acid.},
author = {Fasching, Peter and Jud, Sebastian and Hauschild, Maik and Kuemmel, Sherko and Schuette, Martin and Warm, Matthias and Hanf, Volker and Grab, Dieter and Krocker, Jutta and Stickeler, Elmar and Kreienberg, Rolf and Mueller, Thomas and Kuehn, Thorsten and Wolf, Christopher and Kahlert, Steffen and Paepke, Stefan and Berghorn, Michael and Muth, Mathias and Baier, Monika and Wackwitz, Birgit and Schulz-Wendtland, Rüdiger and Beckmann, Matthias and Lux, Michael P.},
doi = {10.1186/1471-2407-14-66},
faupublication = {yes},
journal = {BMC Cancer},
note = {EVALuna2:14433},
pages = {66},
peerreviewed = {Yes},
title = {{FemZone} trial: a randomized phase {II} trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients},
volume = {14},
year = {2014}
}
@article{faucris.232498938,
abstract = {The assessment of circulating tumor cells (CTCs) has been shown to enable monitoring of treatment response and early detection of metastatic breast cancer (MBC) recurrence. The aim of this study was to compare a well-established CTC detection method based on immunomagnetic isolation with a new, filtration-based platform.In this prospective study, two 7.5 ml blood draws were obtained from 60 MBC patients and CTC enumeration was assessed using both the CellSearch® and the newly developed filtration-based platform. We analyzed the correlation of CTC-positivity between both methods and their ability to predict prognosis. Overall survival (OS) was calculated and Kaplan-Meier curves were estimated with thresholds of >=1 and >=5 detected CTCs.The CTC positivity rate of the CellSearch® system was 56.7% and of the filtration-based platform 66.7%. There was a high correlation of CTC enumeration obtained with both methods. The OS for patients without detected CTCs, regardless of the method used, was significantly higher compared to patients with one or more CTCs (p < 0.001). The median OS of patients with no CTCs vs. >= 1 CTC assessed by CellSearch® was 1.83 years (95% CI: 1.63-2.02) vs. 0.74 years (95% CI: 0.51-1.52). If CTCs were detected by the filtration-based method the median OS times were 1.88 years (95% CI: 1.74-2.03) vs. 0.59 years (95% CI: 0.38-0.80).The newly established EpCAM independently filtration-based system is a suitable method to determine CTC counts for MBC patients. Our study confirms CTCs as being strong predictors of prognosis in our population of MBC patients.},
author = {Hübner, Hanna and Fasching, Peter and Gumbrecht, Walter and Jud, Sebastian and Rauh, Claudia and Matzas, Mark and Paulicka, Peter and Friedrich, Katja and Lux, Michael P. and Volz, Bernhard and Gaß, Paul and Häberle, Lothar and Meier-Stiegen, Franziska and Hartkopf, Andreas and Neubauer, Hans and Almstedt, Katrin and Beckmann, Matthias and Fehm, Tanja N. and Rübner, Matthias},
doi = {10.1186/s12885-018-4115-1},
faupublication = {yes},
journal = {BMC Cancer},
note = {EVALuna2:51529},
pages = {204},
peerreviewed = {Yes},
title = {{Filtration} based assessment of {CTCs} and {CellSearch}® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients},
volume = {18},
year = {2018}
}
@article{faucris.290417029,
abstract = {Aim: This prospective clinical study aimed to evaluate whether it would be possible to reduce the rate of re-excisions using CMOS technology, a specimen radiography system (SRS) or digital breast tomosynthesis (DBT) compared to a conventional full field digital mammography (FFDM) system. Material and Method: Between 12/2012 and 2/2013 50 patients were diagnosed with invasive breast cancer (BI-RADS™ 5). After histological verification, all patients underwent breast-conserving therapy with intraoperative imaging using 4 different systems and differing magnifications: 1. Inspiration™ (Siemens, Erlangen, Germany), amorphous selenium, tungsten source, focus 0.1 mm, resolution 85 m pixel pitch, 8 lp/mm; 2. BioVision™ (Bioptics, Tucson, AZ, USA), CMOS technology, photodiode array, flat panel, tungsten source, focus 0.05, resolution 50 m pixel pitch, 12 lp/mm; 3. the Trident™ specimen radiography system (SRS) (Hologic, Bedford, MA, USA), amorphous selenium, tungsten source, focus 0.05, resolution 70 m pixel pitch, 7.1 lp/mm; 4. tomosynthesis (Siemens, Erlangen, Germany), amorphous selenium, tungsten source, focus 0.1 mm, resolution 85 m pixel pitch, 8 lp/mm, angular range 50 degrees, 25 projections, scan time > 20 s, geometry: uniform scanning, reconstruction: filtered back projection. The 600 radiographs were prospectively shown to 3 radiologists. Results: Of the 50 patients with histologically proven breast cancer (BI-RADS™ 6), 39 patients required no further surgical therapy (re-excision) after breast-conserving surgery. A retrospective analysis (n = 11) showed a significant (p < 0.05) increase of sensitivity with the BioVision™, the Trident™ and tomosynthesis compared to the Inspiration™ at a magnification of 1.0: 2.0 or 1.0: 1.0 (tomosynthesis) (2.6, 3.3 or 3.6 %), i.e. re-excision would not have been necessary in 2, 3 or 4 patients, respectively, compared to findings obtained with a standard magnification of 1.0: 1.0. Conclusion: The sensitivity of the BioVision™, the Trident™ and tomosynthesis was significantly (p < 0.05) higher and the rate of re-excisions was reduced compared to FFDM using a conventional detector at a magnification of 2.0 but without zooming. © Georg Thieme Verlag KG Stuttgart New York.},
author = {Schulz-Wendtland, Rüdiger and Dilbat, G. and Bani, Mayada and Fasching, Peter and Heusinger, K. and Lux, Michael P. and Löhberg, Christian and Brehm, Barbara and Hammon, Matthias and Saake, Marc and Dankerl, Peter and Jud, Sebastian and Rauh, Claudia and Bayer, Christian M. and Beckmann, Matthias and Uder, Michael and Meier-Meitinger, Martina},
doi = {10.1055/s-0032-1328600},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
keywords = {Breast; breast cancer; breast malignancy; mammography},
note = {CRIS-Team Scopus Importer:2023-03-08},
pages = {422-427},
peerreviewed = {Yes},
title = {{Full} field digital mammography ({FFDM}) versus cmos technology, specimen radiography system ({SRS}) and tomosynthesis ({DBT}) - {Which} system can optimise surgical therapy?},
volume = {73},
year = {2013}
}
@article{faucris.123803944,
abstract = {Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is generally ER positive (ER+) and often associated with lobular carcinoma in situ (LCIS). Genome-wide association studies have identified more than 70 common polymorphisms that predispose to breast cancer, but these studies included predominantly ductal (IDC) carcinomas. To identify novel common polymorphisms that predispose to ILC and LCIS, we pooled data from 6,023 cases (5,622 ILC, 401 pure LCIS) and 34,271 controls from 36 studies genotyped using the iCOGS chip. Six novel SNPs most strongly associated with ILC/LCIS in the pooled analysis were genotyped in a further 516 lobular cases (482 ILC, 36 LCIS) and 1,467 controls. These analyses identified a lobular-specific SNP at 7q34 (rs11977670, OR (95%CI) for ILC = 1.13 (1.09-1.18), P = 6.0 × 10(-10); P-het for ILC vs IDC ER+ tumors = 1.8 × 10(-4)). Of the 75 known breast cancer polymorphisms that were genotyped, 56 were associated with ILC and 15 with LCIS at P<0.05. Two SNPs showed significantly stronger associations for ILC than LCIS (rs2981579/10q26/FGFR2, P-het = 0.04 and rs889312/5q11/MAP3K1, P-het = 0.03); and two showed stronger associations for LCIS than ILC (rs6678914/1q32/LGR6, P-het = 0.001 and rs1752911/6q14, P-het = 0.04). In addition, seven of the 75 known loci showed significant differences between ER+ tumors with IDC and ILC histology, three of these showing stronger associations for ILC (rs11249433/1p11, rs2981579/10q26/FGFR2 and rs10995190/10q21/ZNF365) and four associated only with IDC (5p12/rs10941679; rs2588809/14q24/RAD51L1, rs6472903/8q21 and rs1550623/2q31/CDCA7). In conclusion, we have identified one novel lobular breast cancer specific predisposition polymorphism at 7q34, and shown for the first time that common breast cancer polymorphisms predispose to LCIS. We have shown that many of the ER+ breast cancer predisposition loci also predispose to ILC, although there is some heterogeneity between ER+ lobular and ER+ IDC tumors. These data provide evidence for overlapping, but distinct etiological pathways within ER+ breast cancer between morphological subtypes.},
author = {Sawyer, Elinor and Roylance, Rebecca and Petridis, Christos and Brook, Mark N. and Nowinski, Salpie and Papouli, Efterpi and Fletcher, Olivia and Pinder, Sarah and Hanby, Andrew and Kohut, Kelly and Gorman, Patricia and Caneppele, Michele and Peto, Julian and Silva, Isabel Dos Santos and Johnson, Nichola and Swann, Ruth and Dwek, Miriam and Perkins, Katherine-Anne and Gillett, Cheryl and Houlston, Richard and Ross, Gillian and De Ieso, Paolo and Southey, Melissa C. and Hopper, John L. and Provenzano, Elena and Apicella, Carmel and Wesseling, Jelle and Cornelissen, Sten and Keeman, Renske and Fasching, Peter and Jud, Sebastian and Ekici, Arif Bülent and Beckmann, Matthias and Kerin, Michael J. and Marme, Federick and Schneeweiss, Andreas and Sohn, Christof and Burwinkel, Barbara and Guenel, Pascal and Truong, Therese and Laurent-Puig, Pierre and Kerbrat, Pierre and Bojesen, Stig E. and Nordestgaard, Borge G. and Nielsen, Sune F. and Flyger, Henrik and Milne, Roger L. and Perez, Jose Ignacio Arias and Menendez, Primitiva and Benitez, Javier and Brenner, Hermann and Dieffenbach, Aida Karina and Arndt, Volker and Stegmaier, Christa and Meindl, Alfons and Lichtner, Peter and Schmutzler, Rita K. and Lochmann, Magdalena and Brauch, Hiltrud and Fischer, Hans-Peter and Ko, Yon-Dschun and Nevanlinna, Heli and Muranen, Taru A. and Aittomaki, Kristiina and Blomqvist, Carl and Bogdanova, Natalia V. and Dork, Thilo and Lindblom, Annika and Margolin, Sara and Mannermaa, Arto and Kataja, Vesa and Kosma, Veli-Matti and Hartikainen, Jaana M. and Chenevix-Trench, Georgia and Lambrechts, Diether and Weltens, Caroline and Van Limbergen, Erik and Hatse, Sigrid and Chang-Claude, Jenny and Rudolph, Anja and Seibold, Petra and Flesch-Janys, Dieter and Radice, Paolo and Peterlongo, Paolo and Bonanni, Bernardo and Volorio, Sara and Giles, Graham G. and Severi, Gianluca and Baglietto, Laura and Mclean, Catriona A. and Haiman, Christopher A. and Henderson, Brian E. and Schumacher, Fredrick and Le Marchand, Loic and Simard, Jacques and Goldberg, Mark S. and Labreche, France and Dumont, Martine and Kristensen, Vessela and Winqvist, Robert and Pylkas, Katri and Jukkola-Vuorinen, Arja and Kauppila, Saila and Andrulis, Irene L. and Knight, Julia A. and Glendon, Gord and Mulligan, Anna Marie and Devillee, Peter and Tollenaar, Rob A. E. M. and Seynaeve, Caroline M. and Kriege, Mieke and Figueroa, Jonine and Chanock, Stephen J. and Sherman, Mark E. and Hooning, Maartje J. and Hollestelle, Antoinette and Van Den Ouweland, Ans M. W. and Van Deurzen, Carolien H. M. and Li, Jingmei and Czene, Kamila and Humphreys, Keith and Cox, Angela and Cross, Simon S. and Reed, Malcolm W. R. and Shah, Mitul and Jakubowska, Anna and Lubinski, Jan and Jaworska-Bieniek, Katarzyna and Durda, Katarzyna and Swerdlow, Anthony and Ashworth, Alan and Orr, Nicholas and Schoemaker, Minouk and Couch, Fergus J. and Hallberg, Emily and Gonzalez-Neira, Anna and Pita, Guillermo and Alonso, M. Rosario and Tessier, Daniel C. and Vincent, Daniel and Bacot, Francois and Bolla, Manjeet K. and Wang, Qin and Dennis, Joe and Michailidou, Kyriaki and Dunning, Alison M. and Hall, Per and Easton, Doug and Pharoah, Paul and Schmidt, Marjanka K. and Tomlinson, Ian and Garcia-Closas, Montserrat},
doi = {10.1371/journal.pgen.1004285},
faupublication = {yes},
journal = {PLoS Genetics},
note = {EVALuna2:9234},
pages = {e1004285},
peerreviewed = {Yes},
title = {{Genetic} predisposition to in situ and invasive lobular carcinoma of the breast},
volume = {10},
year = {2014}
}
@article{faucris.212408660,
abstract = {PURPOSE: The growing popularity and acceptance of integrative medicine is evident both among patients and among the oncologists treating them. As little data are available regarding health-care professionals' knowledge, attitudes, and practices relating to the topic, a nationwide online survey was designed.
METHODS: Over a period of 11 weeks (from July 15 to September 30, 2014) a self-administered, 17-item online survey was sent to all 676 members of the Research Group on Gynecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie) in the German Cancer Society. The questionnaire items addressed the use of integrative therapy methods, fields of indications for them, advice services provided, level of specific qualifications, and other topics.
RESULTS: Of the 104 respondents (15.4%) using integrative medicine, 93% reported that integrative therapy was offered to breast cancer patients. The second most frequent type of tumor in connection with which integrative therapy methods were recommended was ovarian cancer, at 80% of the participants using integrative medicine. Exercise, nutritional therapy, dietary supplements, herbal medicines, and acupuncture were the methods the patients were most commonly advised to use.
CONCLUSION: There is considerable interest in integrative medicine among gynecological oncologists, but integrative therapy approaches are at present poorly implemented in routine clinical work. Furthermore there is a lack of specific training. Whether future efforts should focus on extending counseling services on integrative medicine approaches in gynecologic oncology or not, have to be discussed. Evidence-based training on integrative medicine should be implemented in order to safely guide patients in their wish to do something by themselves.},
author = {Klein, Evelyn and Beckmann, Matthias and Bader, Werner and Brucker, Cosima and Dobos, Gustav and Fischer, Dorothea and Hanf, Volker and Hasenburg, Annette and Jud, Sebastian and Kalder, Matthias and Kiechle, Marion and Kuemmel, Sherko and Mueller, Andreas and Mueller, Myrjam-Alice T. and Paepke, Daniela and Rotmann, Andre-Robert and Schuetz, Florian and Scharl, Anton and Voiss, Petra and Wallwiener, Markus and Witt, Claudia and Hack, Carolin},
doi = {10.1007/s00404-017-4420-y},
faupublication = {yes},
journal = {Archives of Gynecology and Obstetrics},
note = {EVALuna2:36130},
pages = {295-301},
peerreviewed = {Yes},
title = {{Gynecologic} oncologists' attitudes and practices relating to integrative medicine: results of a nationwide {AGO} survey},
volume = {296},
year = {2017}
}
@article{faucris.119698524,
abstract = {Cost increases in the healthcare system are leading to a need to distribute financial resources in accordance with the value of each service performed. Health-economic decision-making models can support these decisions. Due to the previous unavailability of health utilities in Germany (scored states of health as a basis for calculating quality-adjusted life-years, QALYs) for women undergoing treatment, international data are often used for such models. However, these may widely deviate from the values for a woman actually living in Germany. It is, therefore, necessary to collect and analyze health utilities in Germany.In a questionnaire survey, health utilities were collected, along with data for a healthy control group, for 580 female patients receiving treatment in the fields of mastology and gynecological oncology using a German version of the EuroQol questionnaire (EQ-5D) and a visual analogue scale (VAS). Data were also collected for the patients' medical history, tumor disease, and treatment.Significant differences with regard to quality of life were measured in relation to the individual tumor entities and in comparison to the controls. Apart from the healthy control group, patients with breast or cervical carcinoma had the best quality of life. In patients with recurrent and metastatic disease, those with breast carcinoma experienced the greatest impairment of their quality of life. According to current treatment, the most important impairment of life quality occurred in patients under radiotherapy and after surgical treatment. There are significant differences from the health utilities recorded for other countries - for example, the state of health declines much more markedly in patients with metastatic disease among American women with breast carcinoma than among German women, in whom recurrent disease and a first diagnosis of metastasis were comparable. Overall, the VAS was able to distinguish more adequately than the EQ-5D questionnaire between the different situations and impairments resulting from diagnosis and therapy.Health utilities are now, for the first time, available for further health-economics analyses in the field of gynecological oncology and mastology for women living in Germany. Important differences in these utilities from those of other countries are evident.},
author = {Hildebrandt, Thomas and Thiel, Falk and Fasching, Peter and Graf, Christiane and Bani, Mayada and Löhberg, Christian and Schrauder, Michael G. and Jud, Sebastian and Hack, Carolin and Beckmann, Matthias and Lux, Michael P.},
faupublication = {yes},
journal = {Anticancer Research},
note = {EVALuna2:17453},
pages = {829-35},
peerreviewed = {Yes},
title = {{Health} utilities in gynecological oncology and mastology in {Germany}},
volume = {34},
year = {2014}
}
@article{faucris.243301628,
abstract = {The immunosuppressive human leukocyte antigens HLA-G and HLA-F are expressed on trophoblast and malignant cells. Four membrane-bound and three soluble HLA-G protein isoforms have been described, which have different immunosuppressive potentials. HLA-F has three transcript variants, resulting in three different protein isoforms. The aim of this study was to evaluate the prognostic and predictive value of HLA-G and HLA-F protein isoform expression patterns in patients with breast cancer. Core biopsies were taken at diagnosis in patients with HER2+ (n = 28), luminal B-like (n = 49) and triple-negative (n = 38) breast cancers who received neoadjuvant chemotherapy. Expression levels of HLA-F and -G were correlated with the pathological complete response (pCR). Protein expression was determined by Western blot analysis, using two antibodies for each HLA, specific for different isoforms. The protein expression of HLA isoforms did not significantly differ between breast cancer subtypes. However, some initial indications were found for an association between the soluble HLA-G6 protein isoform and pCR in HER2+ breast cancer. The study provides preliminary evidence for the evaluation of HLA-G isoform expression, in particular HLA-G6, as a possible new marker for pCR in HER2+ breast cancer.},
author = {Würfel, Franziska and Hübner, Hanna and Häberle, Lothar and Gaß, Paul and Hein, Alexander and Jud, Sebastian and Hack, Carolin and Wunderle, Marius and Schulz-Wendtland, Rüdiger and Erber, Ramona and Hartmann, Arndt and Ekici, Arif Bülent and Beckmann, Matthias and Fasching, Peter and Rübner, Matthias},
doi = {10.1038/s41598-020-72837-3},
faupublication = {yes},
journal = {Scientific Reports},
note = {CRIS-Team Scopus Importer:2020-10-02},
peerreviewed = {Yes},
title = {{HLA}-{G} and {HLA}-{F} protein isoform expression in breast cancer patients receiving neoadjuvant treatment},
volume = {10},
year = {2020}
}
@article{faucris.261677378,
abstract = {Estrogen exposure has at least a moderate effect on the risk for ovarian cancer, and antiestrogen therapy may be helpful in treating the disease. It is known from breast cancer that previous hormone replacement therapy (HRT) may influence the molecular profile and prognostic behavior of these tumors. The aim of this study was therefore to investigate the influence of previous HRT on the prognosis in a cohort of patients with invasive epithelial ovarian cancer. Among 547 patients who were treated for ovarian malignancies at a single institution from 1995 to 2008, a total of 244 postmenopausal patients with epithelial cancer and under the age of 75 were identified for whom information about HRT before the onset of the disease was available. HRT was correlated with tumor and patient characteristics. Analyses of overall survival and progression-free survival were carried out using Cox proportional hazards models. Age, tumor stage, and resection status correlated significantly with HRT in the univariate analysis. Patients with previous HRT were more likely to have a lower stage, to be younger, and to have optimal debulking. With regard to survival, HRT had a positive effect on overall survival, specifically in the subgroup of patients with optimal debulking. No correlation was seen in relation to progression-free survival. Sex hormone exposure through HRT may influence the behavior of ovarian cancers after the onset of the disease. This study supports the hypothesis that ovarian cancer is a hormonally influenced tumor. © 2012 Lippincott Williams & Wilkins.},
author = {Hein, Alexander and Thiel, Falk and Bayer, Christian M. and Fasching, Peter and Häberle, Lothar and Lux, Michael P. and Renner, Stefan and Jud, Sebastian and Schrauder, Michael G. and Müller, Andreas and Wachter, David and Strehl, Johanna and Hartmann, Arndt and Beckmann, Matthias and Rauh, Claudia},
doi = {10.1097/CEJ.0b013e328355ec22},
faupublication = {no},
journal = {European Journal of Cancer Prevention},
keywords = {estrogen; hormone replacement therapy; ovarian cancer; pathogenesis; prognosis},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {52-58},
peerreviewed = {Yes},
title = {{Hormone} replacement therapy and prognosis in ovarian cancer patients},
volume = {22},
year = {2013}
}
@article{faucris.240769031,
abstract = {Purpose: In breast cancer, a pathological complete response (pCR) has been described as generally resulting in a favorable prognosis. However, there are subgroups, such as patients with a mutation in BRCA1 or BRCA2,in which the effect of pCR on the prognosis is suspected to be weaker. Patients with a family history of breast and/or ovarian cancer may therefore react differently in relation to pCR and prognosis, and this is investigated in this study. Patients and Methods: Breast cancer patients were identified from a clinical breast cancer registry. The study subjects had been treated with neoadjuvant chemotherapy from 2001 to 2018 and their pathological and clinical information as well as medical family history were available. They were considered to have a positive family history if they had at least 1 first-degree relative with breast and/or ovarian cancer. Multivariate logistic regression analyses were performed to study the association between family history, pCR (ypT0; ypN0), and disease-free survival (DFS). Results: Of 1,480 patients, 228 (15.4%) had a positive family history. The pCR rates were 24.9% in all patients, and 24.4% and 27.6% in those without/with a family history, respectively. Family history was not associated with a higher pCR rate (adjusted odds ratio [OR] 1.23; 95% confidence interval [CI] 0.85-1.76; p = 0.27) or a different disease-free survival (DFS; adjusted hazard ratio [HR] 1.15; 95% CI 0.88-1.52; p = 0.30). pCR did not affect the prognosis differently in relation to family history. Conclusions: In this retrospective analysis, family history was not associated with pCR and DFS. pCR improved survival, independently of family history.},
author = {Wunderle, Marius and Häberle, Lothar and Hein, Alexander and Jud, Sebastian and Lux, Michael P. and Hack, Carolin and Emons, Julius and Heindl, Felix and Nabieva, Naiba and Löhberg, Christian and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Beckmann, Matthias and Fasching, Peter and Gaß, Paul},
doi = {10.1159/000507475},
faupublication = {yes},
journal = {Breast Care},
keywords = {Breast cancer; Family history; Neoadjuvant chemotherapy; Ovarian cancer; Pathological complete response; Prognosis},
note = {CRIS-Team Scopus Importer:2020-07-24},
peerreviewed = {Yes},
title = {{Influence} of {Family} {History} of {Breast} or {Ovarian} {Cancer} on {Pathological} {Complete} {Response} and {Long}-{Term} {Prognosis} in {Breast} {Cancer} {Patients} {Treated} with {Neoadjuvant} {Chemotherapy}},
year = {2020}
}
@inproceedings{faucris.244617493,
address = {STUTTGART},
author = {Gaß, Paul and Haberle, L. and Hein, Alexander and Jud, Sebastian and Lux, M. P. and Hack, Caroline and Emons, J. and Heindl, Felix and Nabieva, Naiba and Löhberg, Christian and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Beckmann, Matthias and Fasching, Peter and Wunderle, Marius},
booktitle = {GEBURTSHILFE UND FRAUENHEILKUNDE},
doi = {10.1055/s-0040-1717891},
faupublication = {yes},
note = {CRIS-Team WoS Importer:2020-10-30},
pages = {E111-E112},
peerreviewed = {unknown},
publisher = {GEORG THIEME VERLAG KG},
title = {{Influence} of the {Family} {Anamnesis} of {Breast} or {Ovarian} {Cancer} on the pathological {Complete} {Remission} and the {Prognosis} in {Patients} with {Breast} {Cancer} after neoadjuvant {Chemotherapy}},
year = {2020}
}
@article{faucris.207712299,
abstract = {BACKGROUND: Combinations *Equal contributors. of different imaging techniques in fusion devices appear to be associated with improvements in diagnostic assessment.
PURPOSE: The aim of this study was to test the feasibility of using an automated standard three-dimensional (3D) ultrasound (US) device fused with standard mammography for the first time in breast cancer patients.
MATERIAL AND METHODS: Digital mammograms and 3D automated US images were obtained in 23 patients with highly suspicious breast lesions. A recently developed fusion machine consisting of an ABVS 3D US transducer from an Acuson S2000 machine and a conventional Mammomat Inspiration device (both Siemens Healthcare GmbH, Erlangen, Germany) were used for the purpose. The feasibility of the examinations, imaging coverage, and patients' experience of the procedure were examined.
RESULTS: In 15 out of 19 patients, the region of interest (ROI) with the tumor marked in the mammogram was visible on US. The examination was experienced positively by the patients, with no unexpected pain or injury. The examination was time-saving and well tolerated.
CONCLUSION: In conclusion, we have shown initial clinical feasibility of an US/radiography fusion prototype with good localization and evaluation of the ROIs. The combined examination was well tolerated. The simultaneous evaluation with mammography and US imaging may be able to improve detection and reduce examiner-related variability.},
author = {Emons, Julius and Wunderle, Marius and Hartmann, Arndt and Radicke, Marcus and Rauh, Claudia and Uder, Michael and Gaß, Paul and Fasching, Peter and Langemann, Hanna and Beckmann, Matthias and Schulz-Wendtland, Rüdiger and Jud, Sebastian},
doi = {10.1177/0284185118762249},
faupublication = {yes},
journal = {Acta Radiologica},
note = {EVALuna2:34810},
pages = {1406-1413},
peerreviewed = {Yes},
title = {{Initial} clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe},
volume = {59},
year = {2018}
}
@article{faucris.242707768,
abstract = {Purpose: Testing is required in medical education. The large number of exams that students face requires effective learning strategies. Various methods of improving knowledge retention and recall have been discussed, two of the most widely evaluated of which are test-enhanced learning and pause procedures. This study investigated the effect of voluntary multiple-choice questions on students’ performance. Methods: In a prospective study from April 2013 to March 2015, 721 students were randomly assigned to receive supplementary online material only (control group) or additional multiple-choice questions (investigative group) accompanying lectures. Their performance in the final exam was evaluated. Results: A total of 675 students were ultimately included, with 299 randomly assigned to the investigative group and 376 to the control group. Students in the investigative group scored significantly better in relation to grades and points (2.11 vs. 2.49; 33 vs 31.31; p < 0.05). The effect declined over time. Conclusion: This is the first study of the use of voluntary multiple-choice questions to improve medical students’ performance. The results support test-enhanced learning and the feasibility of implementing multiple-choice questions in lectures.},
author = {Jud, Sebastian and Cupisti, Susanne and Frobenius, Wolfgang and Winkler, Andrea and Schultheis, Franziska and Antoniadis, Sophia and Beckmann, Matthias and Heindl, Felix},
doi = {10.1007/s00404-020-05758-1},
faupublication = {yes},
journal = {Archives of Gynecology and Obstetrics},
keywords = {Gynecology; Lecture; Multiple choice; Obstetrics; Teaching; Testing},
note = {CRIS-Team Scopus Importer:2020-09-18},
peerreviewed = {Yes},
title = {{Introducing} multiple-choice questions to promote learning for medical students: effect on exam performance in obstetrics and gynecology},
year = {2020}
}
@article{faucris.249967824,
abstract = {Background/Aims: Macromastia can cause physical and psychological problems. Conservative treatments such as physiotherapy and painkillers lead to substantial long-term costs, without any proven medical benefit. In contrast, surgical treatment with reduction mammoplasty leads to improvements in nearly all respects. This study analyzed the costs of reduction mammoplasty and calculated an incremental cost-utility ratio for the treatment. Patients and Methods: The data on 76 patients who underwent reduction mammoplasty between 2008 and 2016 were collected using a two-part questionnaire (preoperative and postoperative) as well as the patients' files. Topics examined besides demographic data included physician visits, medical imaging, integrative medical procedures, remedial procedures, rehabilitation and convalescent measures, drug intake, medical aids, exercise activity, and sick leave days before and after surgery. The data were used to calculate costs per year after surgical treatment for symptomatic macromastia. Costs of surgery, including the process of obtaining insurance reimbursement and postoperative complications, were taken into account to calculate the one-time costs of reduction mammoplasty. Results: The patients' quality of life and satisfaction with the breasts improve after surgery. The one-time costs of reduction mammoplasty per patient amount to EUR 5,885, and the annual costs after surgery are EUR 200. The incremental cost-utility ratio for surgical treatments shows a saving of EUR 380 per quality-adjusted life-year (QALY) gained. Conclusions: These results show that reduction mammoplasty is a treatment that not only improves a patient's quality of life but also saves money in the longer term in comparison with expensive and ineffective conservative treatment for macromastia.},
author = {Lux, Michael P. and Brendle-Behnisch, Anne and Hack, Carolin and Preuss, Caroline and Arkudas, Andreas and Horch, Raymund E. and Beckmann, Matthias and Jud, Sebastian},
doi = {10.1159/000514260},
faupublication = {yes},
journal = {Breast Care},
note = {CRIS-Team WoS Importer:2021-02-19},
peerreviewed = {Yes},
title = {{Is} {Reduction} {Mammoplasty} {Cost}-{Effective}? {A} {Cost}-{Utility} {Analysis} of {Surgical} {Treatment} for {Macromastia} in {Germany}},
year = {2021}
}
@article{faucris.108931504,
abstract = {Medical research studies are becoming increasingly important for optimizing the prevention, diagnosis and treatment of illnesses. Participation in research studies can have many benefits for patients. In randomized and controlled clinical studies, they can receive the best possible medical care currently available. However, only a small proportion of patients nowadays are treated within the framework of medical research. The primary endpoint of this study was to discover what level of knowledge patients have about clinical studies and how they currently perceive them, in order to identify ways of optimizing the information provided about studies from the patients' point of view.The study included 2546 patients (breast cancer 21.6%, gynecological cancer 8.3%, obstetrics 32.7%, endometriosis 7.8%, fertility treatment 3.2%, other benign gynecological illnesses 19.2%, no information for 7.2%) in the outpatient clinic (45.2%) and in the in-patient sector (54.8%) at the Department of Gynecology at Erlangen University Hospital and associated centers. In the single-center study, conducted between January 2011 and January 2012, the patients were asked about their level of knowledge regarding the background to medical research studies and the ways in which they are carried out and used. The patients were also asked how they perceived medical studies and how they thought study conditions might be optimized. The three-page questionnaire was included in the feedback sheet received by patients as part of the hospital's quality management system.As a whole, the group only had moderate knowledge about clinical studies. A majority of the respondents considered that studies were valuable (91.6%), but only a few were also willing to take part in them (58.4%). Knowledge and willingness to participate strongly depended on age (P < 0.001), educational level (P < 0.001) and patient group (P < 0.001). Most patients would prefer to decide about participating in studies through a discussion with their outpatient physicians.The information that patients have about clinical studies affects whether they participate in them. It is therefore extremely important for patients to be well informed, for their anxieties about participation to be relieved, and for the benefits of participation to be explained to them.},
author = {Lux, Michael P. and Hildebrandt, Thomas and Knetzger, Sandra-Maria and Schrauder, Michael G. and Jud, Sebastian and Hein, Alexander and Rauh, Claudia and Fasching, Peter and Beckmann, Matthias and Thiel, Falk},
doi = {10.1186/s12885-015-1584-3},
faupublication = {yes},
journal = {BMC Cancer},
note = {EVALuna2:17441},
pages = {587},
peerreviewed = {Yes},
title = {{Knowledge} and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases},
volume = {15},
year = {2015}
}
@article{faucris.238710498,
abstract = {BACKGROUND: Logbooks are being increasingly widely used as a means of improving medical education and further training. They will in all probability continue to be mandatory in the Practical Year (PJ) in Germany even after the upcoming amendment of the Medical Licensing Regulations (ÄAppO). However, there are different approaches to their design and use, and these are also currently undergoing considerable change. This study for the first time examines and discusses the influence of logbooks on students' evaluation of a gynecology internship. METHODS: The study was based on a well-established two-part 1-week internship course, with initially unstructured morning classes on wards and duty areas, along with precisely planned afternoon classes with skills training by peer teachers and seminars supervised by duty-exempted physicians. The postgraduate lecturers were prepared for the introduction of the logbook in a special course, and the aim was to optimize morning classes by introducing learning objectives adapted to the respective locations. The effects over 38 weeks of practical training were examined in evaluations by 235 prospectively group-randomized students with and without logbooks (n = 166 and n = 66, respectively; three datasets were not evaluable). RESULTS: In the cohort comparison, the logbook group responded significantly more positively toward the internship at the start of the course (P = 0.046). In the final evaluation, however, medical supervision during the entire internship was rated significantly more poorly (P = 0.007). The logbook cohort also considered that guidance based on learning objectives was significantly worse, as was the extent to which wards and duty areas were prepared for the students (P = 0.001 and P = 0.029). CONCLUSIONS: Introducing a logbook to optimize clinical teaching in internships may raise expectations that cannot always be met. In addition to adapting the learning objectives to a general framework that is less favorable in comparison with the Practical Year, the least that is required appears to be simultaneous and continuous mentoring of the lecturers, as well as an increase in staffing resources.},
author = {Jud, Sebastian and Cupisti, Susanne and Frobenius, Wolfgang and Benn, Sigrid and Winkler, Andrea and Antoniadis, Sophia and Beckmann, Matthias and Heindl, Felix},
doi = {10.1186/s40001-020-00413-6},
faupublication = {yes},
journal = {European Journal of Medical Research},
keywords = {Gynecology; Internship; Logbook; Teaching},
note = {CRIS-Team Scopus Importer:2020-05-26},
pages = {15-},
peerreviewed = {Yes},
title = {{Logbooks} alone are not enough: initial experience with implementing a logbook for medical students in a clinical internship in gynecology and obstetrics},
volume = {25},
year = {2020}
}
@article{faucris.107609744,
abstract = {Ectopic pregnancy is an acute, potentially life-threatening condition. The aim of this study was to compare the results of surgery and methotrexate treatment in women with ectopic pregnancy, along with a review of the literature.164 women with ectopic pregnancy, treated from 2000 to 2008 at the university gynecology department, were examined in a retrospective analysis. Patients with diagnosed ectopic pregnancy underwent one of the following treatments: Salpingotomy, salpingectomy or administration of a single dose of 30 mg methotrexate. The main outcome measures were treatment success rate, rate of patients wishing to have children after the ectopic pregnancy, and rates of pregnancy, live births, recurrent ectopic pregnancy, miscarriage, use of assisted reproduction and side effects.There were no significant differences in success rates between the groups (methotrexate 83.9 %, salpingotomy 88.2 %, salpingectomy 96.8 %). Significantly more patients in the salpingotomy group wished to become pregnant afterward than in the salpingectomy group. No significant differences were observed between the groups in the rates of intrauterine pregnancy, live births, recurrences, miscarriages, or side effects.With defined inclusion criteria, similar results can be achieved with low-dose single administration of 30 mg methotrexate in comparison with surgical treatment for ectopic pregnancy. On the basis of the data presented here, further research to establish optimal dosages for methotrexate is needed.},
author = {Lermann, Johannes and Segl, Petra and Jud, Sebastian and Beckmann, Matthias and Oppelt, Peter and Thiel, Falk and Renner, Stefan and Mueller, Andreas},
doi = {10.1007/s00404-013-2982-x},
faupublication = {yes},
journal = {Archives of Gynecology and Obstetrics},
note = {EVALuna2:17460},
pages = {329-35},
peerreviewed = {Yes},
title = {{Low}-dose methotrexate treatment in ectopic pregnancy: a retrospective analysis of 164 ectopic pregnancies treated between 2000 and 2008},
volume = {289},
year = {2014}
}
@article{faucris.244850776,
abstract = {Purpose: Symptomatic macromastia causes physical and psychological problems that can lead to restrictions in the patients’ social and working lives and a reduced quality of life. Associated medical treatments also have a considerable impact on health-care costs. Several studies have assessed these costs, but the total disease costs of macromastia have never been evaluated on the basis of real-world data. Methods: The data for 76 patients who underwent reduction mammoplasty between 2008 and 2016 were collected using a two-part questionnaire (preoperative and postoperative), as well as the patient files. Topics surveyed, besides demographic data, included physician visits, medical imaging, medical procedures, medical treatments, rehabilitation and convalescent measures, drug intake, medical aids, exercise activity, and sick leave days before surgery, to calculate the costs per year of conservative treatment of symptomatic macromastia. Results: The mean time from start of symptoms to surgery was 11.82 years. The data for this group of patients with symptomatic macromastia show that costs per patient amount to €1677.55 per year. These costs include medical consultation, radiological imaging, medical treatments and procedures, physical therapy and rehabilitation, medication, special brassieres, exercise classes costs for sick leave due to problems with macromastia, and travel expenses. Conclusions: These results show that considerable health-care costs arise due to macromastia with conservative treatment. Overall, macromastia costs €1677.55 per patient/year. In particular, lost productivity due to sick days and the costs of physiotherapy are factors driving the high costs.},
author = {Jud, Sebastian and Brendle-Behnisch, Anne and Hack, Carolin and Preuss, Caroline and Arkudas, Andreas and Horch, Raymund E. and Beckmann, Matthias and Lux, Michael P.},
doi = {10.1007/s00404-020-05841-7},
faupublication = {yes},
journal = {Archives of Gynecology and Obstetrics},
keywords = {Breast reduction mammoplasty; Conservative treatment; Disease costs; Gigantomastia; Health care; Macromastia},
note = {CRIS-Team Scopus Importer:2020-11-06},
peerreviewed = {Yes},
title = {{Macromastia}: an economic burden? {A} disease cost analysis based on real-world data in {Germany}},
year = {2020}
}
@article{faucris.294861978,
author = {Preuss, Caroline and Wunderle, Marius and Hack, Carolin and Beckmann, Matthias and Wenkel, Evelyn and Jud, Sebastian and Heindl, Felix},
doi = {10.1055/a-1924-3194},
faupublication = {yes},
journal = {Deutsche Medizinische Wochenschrift},
note = {CRIS-Team WoS Importer:2023-03-31},
pages = {301-305},
peerreviewed = {unknown},
title = {{Mammary} carcinoma in men},
volume = {148},
year = {2023}
}
@article{faucris.290418535,
abstract = {Aim: Nodal status remains one of the most important prognostic factors in breast cancer. The cellular and molecular reasons for the spread of tumor cells to the lymph nodes are not well understood and there are only few predictors in addition to tumor size and multifocality that give an insight into additional mechanisms of lymphatic spread. Aim of our study was therefore to investigate whether breast characteristics such as mammographic density (MD) add to the predictive value of the presence of lymph node metastases in patients with primary breast cancer. Methods: In this retrospective study we analyzed primary, metastasis-free breast cancer patients from one breast center for whom data on MD and staging information were available. A total of 1831 patients were included into this study. MD was assessed as percentage MD (PMD) using a semiautomated method and two readers for every patient. Multiple logistic regression analyses with nodal status as outcome were used to investigate the predictive value of PMD in addition to age, tumor size, Ki-67, estrogen receptor (ER), progesterone receptor (PR), grading, histology, and multi-focality. Results: Multifocality, tumor size, Ki-67 and grading were relevant predictors for nodal status. Adding PMD to a prediction model which included these factors did not significantly improve the prediction of nodal status (p = 0.24, likelihood ratio test). Conclusion: Nodal status could be predicted quite well with the factors multifocality, tumor size, Ki-67 and grading. PMD does not seem to play a role in the lymphatic spread of tumor cells. It could be concluded that the amount of extracellular matrix and stromal cell content of the breast which is reflected by MD does not influence the probability of malignant breast cells spreading from the primary tumor to the lymph nodes. © Georg Thieme Verlag KG Stuttgart · New York.},
author = {Hack, Carolin and Häberle, Lothar and Geisler, K. and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Fasching, Peter and Uder, Michael and Wachter, David and Jud, Sebastian and Löhberg, Christian and Lux, Michael P. and Rauh, Claudia and Beckmann, Matthias and Heusinger, K.},
doi = {10.1055/s-0032-1328291},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
keywords = {breast cancer; estrogen receptor; Ki-67; mammographic density; nodal status; progesterone receptor},
note = {CRIS-Team Scopus Importer:2023-03-08},
pages = {136-141},
peerreviewed = {Yes},
title = {{Mammographic} {Density} and {Prediction} of {Nodal} {Status} in {Breast} {Cancer} {Patients}},
volume = {73},
year = {2013}
}
@inproceedings{faucris.244614015,
address = {STUTTGART},
author = {Heindl, Felix and Fasching, Peter and Hein, Alexander and Hack, Caroline and Heusinger, K. and Gaß, Paul and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Erber, Ramona and Beckmann, Matthias and Meyer, J. and Häberle, Lothar and Jud, Sebastian},
booktitle = {GEBURTSHILFE UND FRAUENHEILKUNDE},
doi = {10.1055/s-0040-1717894},
faupublication = {yes},
note = {CRIS-Team WoS Importer:2020-10-30},
pages = {E112-E113},
peerreviewed = {unknown},
publisher = {GEORG THIEME VERLAG KG},
title = {{Mammographic} {Density} and {Prognosis} in {Patients} with primary {Breast} {Cancer} - {Loss} of {Risk} with increasing {Age}},
year = {2020}
}
@article{faucris.261537223,
abstract = {Purpose: Mammographic density (MD) is one of the strongest risk factors for breast cancer (BC). However, the influence of MD on the BC prognosis is unclear. The objective of this study was therefore to investigate whether percentage MD (PMD) is associated with a difference in disease-free or overall survival in primary BC patients. Methods: A total of 2525 patients with primary, metastasis-free BC were followed up retrospectively for this analysis. For all patients, PMD was evaluated by two readers using a semi-automated method. The association between PMD and prognosis was evaluated using Cox regression models with disease-free survival (DFS) and overall survival (OS) as the outcome, and the following adjustments: age at diagnosis, year of diagnosis, body mass index, tumor stage, grading, lymph node status, hormone receptor and HER2 status. Results: After median observation periods of 9.5 and 10.0 years, no influence of PMD on DFS (p = 0.46, likelihood ratio test (LRT)) or OS (p = 0.22, LRT), respectively, was found. In the initial unadjusted analysis higher PMD was associated with longer DFS and OS. The effect of PMD on DFS and OS disappeared after adjustment for age and was caused by the underlying age effect. Conclusions: Although MD is one of the strongest independent risk factors for BC, in our collective PMD is not associated with disease-free and overall survival in patients with BC.},
author = {Heindl, Felix and Fasching, Peter and Hein, Alexander and Hack, Carolin and Heusinger, Katharina and Gaß, Paul and Pöschke, Patrik and Stübs, Frederik and Schulz-Wendtland, Rüdiger and Hartmann, Arndt and Erber, Ramona and Beckmann, Matthias and Meyer, Julia and Häberle, Lothar and Jud, Sebastian and Emons, Julius},
doi = {10.1016/j.breast.2021.06.004},
faupublication = {yes},
journal = {BREAST },
keywords = {Breast cancer; Breast cancer risk; Mammographic breast density; Mammographic density; Prognosis},
note = {CRIS-Team Scopus Importer:2021-07-16},
pages = {51-57},
peerreviewed = {Yes},
title = {{Mammographic} density and prognosis in primary breast cancer patients},
volume = {59},
year = {2021}
}
@article{faucris.261681154,
abstract = {Mammographic percent density (MD) is recognized as one of the strongest risk factors associated with breast cancer. This matched case-control study investigated whether MD represents an independent risk factor. Mammograms were obtained from 1025 breast cancer patients and from 520 healthy controls. MD was measured using a quantitative computer-based threshold method (0-100%). Breast cancer patients had a higher MD than healthy controls (38 vs. 32%, P<0.01). MD was significantly higher in association with factors such as age over 60 years, body mass index (BMI) of 25-30 kg/m, nulliparity or low parity (one to two births). Average MD was inversely associated with age, BMI, parity and positively associated with age at first full-term pregnancy. MD was higher in women with at least one first-degree relative affected, but only among patients and not in the group of healthy controls (P<0.01/P=0.61). In women with an MD of 25% or more, the risk of breast cancer was doubled compared with women with an MD of less than 10% (odds ratio: 2.1; 95% confidence interval: 1.3-3.4; P<0.01); in the postmenopausal subgroup, the risk was nearly tripled (odds ratio: 2.7; 95% confidence interval: 1.6-4.7; P<0.001). This study provides further evidence that MD is an important risk factor for breast cancer. These results indicate strong associations between MD and the risk of breast cancer in a matched case-control study in Germany © 2010 Wolters Kluwer Health.},
author = {Heusinger, Katharina and Löhberg, Christian and Häberle, Lothar and Jud, Sebastian and Klingsiek, Peter and Hein, Alexander and Bayer, Christian M. and Rauh, Claudia and Uder, Michael and May, Matthias and Adamietz, Boris and Schulz-Wendtland, Rüdiger and Wittenberg, Thomas and Wagner, Florian and Beckmann, Matthias and Fasching, Peter A. and Cavallaro, Alexander Josef},
doi = {10.1097/CEJ.0b013e328341e2ce},
faupublication = {no},
journal = {European Journal of Cancer Prevention},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {1-8},
peerreviewed = {Yes},
title = {{Mammographic} density as a risk factor for breast cancer in a {German} case-control study},
volume = {20},
year = {2011}
}
@article{faucris.111173304,
abstract = {Although mammography screening programs do not include ultrasound examinations, some diagnostic units do provide women with both mammography and ultrasonography. This article is concerned with estimating the risk of a breast cancer patient diagnosed in a hospital-based mammography unit having a tumor that is visible on ultrasound but not on mammography. A total of 1,399 women with invasive breast cancer from a hospital-based diagnostic mammography unit were included in this retrospective study. For inclusion, mammograms from the time of the primary diagnosis had to be available for computer-assisted assessment of percentage mammographic density (PMD), as well as Breast Imaging Reporting and Data System (BIRADS) assessment of mammography. In addition, ultrasound findings were available for the complete cohort as part of routine diagnostic procedures, regardless of any patient or imaging characteristics. Logistic regression analyses were conducted to identify predictors of mammography failure, defined as BIRADS assessment 1 or 2. The probability that the visibility of a tumor might be masked at diagnosis was estimated using a regression model with the identified predictors. Tumors were only visible on ultrasound in 107 cases (7.6%). PMD was the strongest predictor for mammography failure, but age, body mass index and previous breast surgery also influenced the risk, independently of the PMD. Risk probabilities ranged from 1% for a defined low-risk group up to 40% for a high-risk group. These findings might help identify women who should be offered ultrasound examinations in addition to mammography.},
author = {Haeberle, Lothar and Fasching, Peter and Brehm, Barbara and Heusinger, Katharina and Jud, Sebastian and Löhberg, Christian and Hack, Carolin and Preuss, Caroline and Lux, Michael P. and Hartmann, Arndt and Vachon, Celine M. and Meier-Meitinger, Martina and Uder, Michael and Beckmann, Matthias and Schulz-Wendtland, Rüdiger},
doi = {10.1002/ijc.30261},
faupublication = {yes},
journal = {International Journal of Cancer},
note = {EVALuna2:6818},
pages = {1967-74},
peerreviewed = {Yes},
title = {{Mammographic} density is the main correlate of tumors detected on ultrasound but not on mammography},
volume = {139},
year = {2016}
}
@article{faucris.205311147,
abstract = {BACKGROUND/AIM: The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine.
PATIENTS AND METHODS: From 03/2004 to 06/2007, a total of 39 patients were recruited and received mitomycin C in combination with capecitabine. The primary end-point was to determinate the tumor response according to Response Evaluation Criteria in Solid Tumors and the rate of toxicities (safety). The secondary study objective was the evaluation of the time to progression (i.e. efficacy).
RESULTS: The median time to progression was 9.3 months (95% confidence interval=6.6-12.0 months) and the median survival was 12.8 months (95% confidence interval=6.8-18.8 months). Most treatment-related adverse events were mild to moderate.
CONCLUSION: Mitomycin C and capecitabine is a good taxane-free option in patients with metastatic breast cancer previously treated with anthracycline.},
author = {Almstedt, Katrin and Fasching, Peter and Scharl, Anton and Rauh, Claudia and Rack, Brigitte and Hein, Alexander and Hack, Carolin and Bayer, Christian M. and Jud, Sebastian and Schrauder, Michael G. and Beckmann, Matthias and Lux, Michael P.},
faupublication = {yes},
journal = {Anticancer Research},
note = {EVALuna2:33006},
pages = {419-25},
peerreviewed = {Yes},
title = {{Mitomycin} {C} and {Capecitabine} ({MiX} {Trial}) for {Therapy} of {Patients} with {Metastasized}, {Breast} {Cancer} {Pretreated} with {Anthracycline}},
volume = {36},
year = {2016}
}
@article{faucris.109452904,
abstract = {Mammographic density measures adjusted for age and body mass index (BMI) are heritable predictors of breast cancer risk, but few mammographic density-associated genetic variants have been identified. Using data for 10,727 women from two international consortia, we estimated associations between 77 common breast cancer susceptibility variants and absolute dense area, percent dense area and absolute nondense area adjusted for study, age, and BMI using mixed linear modeling. We found strong support for established associations between rs10995190 (in the region of ZNF365), rs2046210 (ESR1), and rs3817198 (LSP1) and adjusted absolute and percent dense areas (all P < 10(-5)). Of 41 recently discovered breast cancer susceptibility variants, associations were found between rs1432679 (EBF1), rs17817449 (MIR1972-2: FTO), rs12710696 (2p24.1), and rs3757318 (ESR1) and adjusted absolute and percent dense areas, respectively. There were associations between rs6001930 (MKL1) and both adjusted absolute dense and nondense areas, and between rs17356907 (NTN4) and adjusted absolute nondense area. Trends in all but two associations were consistent with those for breast cancer risk. Results suggested that 18% of breast cancer susceptibility variants were associated with at least one mammographic density measure. Genetic variants at multiple loci were associated with both breast cancer risk and the mammographic density measures. Further understanding of the underlying mechanisms at these loci could help identify etiologic pathways implicated in how mammographic density predicts breast cancer risk.},
author = {Stone, Jennifer and Thompson, Deborah J. and Silva, Isabel Dos Santos and Scott, Christopher and Tamimi, Rulla M. and Lindstrom, Sara and Kraft, Peter and Hazra, Aditi and Li, Jingmei and Eriksson, Louise and Czene, Kamila and Hall, Per and Jensen, Matt and Cunningham, Julie and Olson, Janet E. and Purrington, Kristen and Couch, Fergus J. and Brown, Judith and Leyland, Jean and Warren, Ruth M. L. and Luben, Robert N. and Khaw, Kay-Tee and Smith, Paula and Wareham, Nicholas J. and Jud, Sebastian and Heusinger, Katharina and Beckmann, Matthias and Douglas, Julie A. and Shah, Kaanan P. and Chan, Heang-Ping and Helvie, Mark A. and Le Marchand, Loic and Kolonel, Laurence N. and Woolcott, Christy and Maskarinec, Gertraud and Haiman, Christopher and Giles, Graham G. and Baglietto, Laura and Krishnan, Kavitha and Southey, Melissa C. and Apicella, Carmel and Andrulis, Irene L. and Knight, Julia A. and Ursin, Giske and Alnaes, Grethe I. Grenaker and Kristensen, Vessela N. and Borresen-Dale, Anne-Lise and Gram, Inger Torhild and Bolla, Manjeet K. and Wang, Qin and Michailidou, Kyriaki and Dennis, Joe and Simard, Jacques and Pharoah, Paul and Dunning, Alison M. and Easton, Douglas F. and Fasching, Peter and Pankratz, V. Shane and Hopper, John L. and Vachon, Celine M.},
doi = {10.1158/0008-5472.CAN-14-2012},
faupublication = {yes},
journal = {Cancer Research},
note = {EVALuna2:17571},
pages = {2457-67},
peerreviewed = {Yes},
title = {{Novel} {Associations} between {Common} {Breast} {Cancer} {Susceptibility} {Variants} and {Risk}-{Predicting} {Mammographic} {Density} {Measures}},
volume = {75},
year = {2015}
}
@article{faucris.261677631,
abstract = {Purpose: Mammographic characteristics are known to be correlated to breast cancer risk. Percent mammographic density (PMD), as assessed by computer-assisted methods, is an established risk factor for breast cancer. Along with this assessment the absolute dense area (DA) of the breast is reported as well. Aim of this study was to assess the predictive value of DA concerning breast cancer risk in addition to other risk factors and in addition to PMD. Methods: We conducted a case control study with hospital-based patients with a diagnosis of invasive breast cancer and healthy women as controls. A total of 561 patients and 376 controls with available mammographic density were included into this study. We describe the differences concerning the common risk factors BMI, parital status, use of hormone replacement therapy (HRT) and menopause between cases and controls and estimate the odds ratios for PMD and DA, adjusted for the mentioned risk factors. Furthermore we compare the prediction models with each other to find out whether the addition of DA improves the model. Results: Mammographic density and DA were highly correlated with each other. Both variables were as well correlated to the commonly known risk factors with an expected direction and strength, however PMD (ρ = 0.56) was stronger correlated to BMI than DA (ρ = 0.11). The group of women within the highest quartil of PMD had an OR of 2.12 (95 % CI: 1.25-3.62). This could not be seen for the fourth quartile concerning DA. However the assessment of breast cancer risk could be improved by including DA in a prediction model in addition to common risk factors and PMD. Conclusions: The inclusion of the parameter DA into a prediction model for breast cancer in addition to established risk factors and PMD could improve the breast cancer risk assessment. As DA is measured together with PMD in the process of computer-assisted assessment of PMD it might be considered to include it as one additional breast cancer risk factor that is obtained from breast imaging. © Georg Thieme Verlag KG Stuttgart · New York.},
author = {Rauh, C. and Hack, Caroline and Häberle, Lothar and Hein, Alexander and Engel, Anne and Schrauder, Michael G. and Fasching, Peter and Jud, Sebastian and Ekici, Arif Bülent and Loehberg, C. R. and Meier-Meitinger, Martina and Ozan-Mergner, Sevil Julia and Schulz-Wendtland, Rüdiger and Uder, Michael and Hartmann, Arndt and Wachter, David Lukas and Beckmann, Matthias and Heusinger, K.},
doi = {10.1055/s-0032-1315129},
faupublication = {no},
journal = {Geburtshilfe und Frauenheilkunde},
keywords = {breast cancer; mammographic density; risk},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {727-733},
peerreviewed = {Yes},
title = {{Percent} mammographic density and dense area as risk factors for breast cancer},
volume = {72},
year = {2012}
}
@article{faucris.220863401,
abstract = {Purpose: Several clinical trials have investigated the prognostic and predictive usefulness of molecular markers. With limited predictive value, molecular markers have mainly been used to identify prognostic subgroups in which the indication for chemotherapy is doubtful and the prognosis is favorable enough for chemotherapy to be avoided. However, limited information is available about which groups of patients may benefit from additional therapy. This study aimed to describe the prognostic effects of Ki-67 in several common subgroups of patients with early breast cancer. Methods: This retrospective study analyzed a single-center cohort of 3140 patients with HER2−, hormone receptor-positive breast cancer. Five-year disease-free survival (DFS) rates were calculated for low (< 10%), intermediate (10–19%), and high (≥ 20%) Ki-67 expression levels, as assessed by immunohistochemistry, and for subgroups relative to age, body mass index, disease stage, tumor grade, and (neo-)adjuvant chemotherapy. It was also investigated whether Ki-67 had different effects on DFS in these subgroups. Results: The 5-year DFS rates for patients with low, intermediate, and high levels of Ki-67 expression were 0.90, 0.89, and 0.77, respectively. Ki-67 was able to further differentiate patients with an intermediate prognosis into different prognostic groups relative to common clinical parameters. Patients with stage II breast cancer had 5-year DFS rates of 0.84, 0.88, and 0.79 for low, intermediate, and high levels of Ki-67 expression. Ki-67 had different prognostic effects in subgroups defined by age and tumor grade. Conclusions: Ki-67 may help identify patients in intermediate prognostic groups with an unfavorable prognosis who may benefit from further therapy.},
author = {Fasching, Peter and Gaß, Paul and Häberle, Lothar and Volz, Bernhard and Hein, Alexander and Hack, Carolin and Lux, Michael P. and Jud, Sebastian and Hartmann, Arndt and Beckmann, Matthias and Slamon, Dennis J. and Erber, Ramona},
doi = {10.1007/s10549-019-05198-9},
faupublication = {yes},
journal = {Breast Cancer Research and Treatment},
keywords = {Breast cancer; Ki-67; Molecular marker; Prognosis; Proliferation},
note = {CRIS-Team Scopus Importer:2019-06-18},
peerreviewed = {Yes},
title = {{Prognostic} effect of {Ki}-67 in common clinical subgroups of patients with {HER2}-negative, hormone receptor-positive early breast cancer},
year = {2019}
}
@article{faucris.261676375,
abstract = {Prediction of the prognosis for metastatic breast cancer patients depends on molecular subtypes similar to those found in patients with primary breast cancer. Several studies have shown that estrogen receptor (ER) and progesterone receptor (PR) status determine the course of the disease and the prognosis. As Ki-67 helps to differentiate molecular subtypes in patients with primary breast cancer, the aim of this study was to assess the prognostic relevance of Ki-67 in the primary tumor in relation to its prognostic relevance for patients with metastatic breast cancer. A total of 467 patients with invasive breast cancer were identified in the database of a single breast cancer center, in whom Ki-67 had been assessed in tumor material from the breast at the time of the primary diagnosis and who had developed a metastasis at any time during the subsequent course. For these patients, tumor and patient characteristics were used to determine prognostic factors relative to overall survival after the diagnosis of distant metastases. Ki-67 was added to this model to investigate whether this might improve the prediction of overall survival. In the multivariate Cox model, age at diagnosis, body mass index, nodal status, tumor size, ER and PR status, and time from diagnosis to metastasis were identified as relevant prognostic factors. Adding Ki-67 to the model improved the prediction of overall survival. There was also a significant and relevant interaction with the PR status. In patients with a low-proliferation primary tumor, a high level of PR expression would indicate an extraordinarily good prognosis (HR 0.39; 95 % CI, 0.23-0.66). In patients with higher-proliferation primary tumors, PR status was not capable of differentiating prognostic groups. Ki-67 is useful in addition to known prognostic factors for breast cancer. It is able to indicate a group of women with a poorer prognosis, specifically in the group of patients with PR-positive breast cancer. © 2013 Springer Science+Business Media New York.},
author = {Loehberg, Christian R. and Almstedt, Katrin and Jud, Sebastian and Haeberle, Lothar and Fasching, Peter and Hack, Carolin and Lux, Michael P. and Thiel, Falk and Schrauder, Michael G. and Brunner, Michaela and Bayer, Christian M. and Hein, Alexander and Heusinger, Katharina and Heimrich, Jutta and Bani, Mayada and Renner, Stefan and Hartmann, Arndt and Beckmann, Matthias and Wachter, David},
doi = {10.1007/s10549-013-2460-y},
faupublication = {no},
journal = {Breast Cancer Research and Treatment},
keywords = {Ki-67; Metastatic breast cancer; Progesterone receptor; Prognosis; Proliferation},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {899-908},
peerreviewed = {Yes},
title = {{Prognostic} relevance of {Ki}-67 in the primary tumor for survival after a diagnosis of distant metastasis},
volume = {138},
year = {2013}
}
@article{faucris.236671412,
abstract = {Breast cancer risk is reduced by number of pregnancies and breastfeeding duration, however studies of breast changes during or after pregnancy are rare. Breast volume changes - although not linked to breast cancer risk - might be an interesting phenotype in this context for correlative studies, as changes of breast volume vary between pregnant women. Serum receptor activator of nuclear factor kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG) were measured prospectively before gestational week 12, and three-dimensional breast volume assessments were performed. A linear regression model including breast volume at the start of pregnancy, RANKL, OPG, and other factors was used to predict breast volume at term. The mean breast volume was 413 mL at gestational week 12, increasing by a mean of 99 mL up to gestational week 40. In addition to body mass index and breast volume at the beginning of pregnancy, RANKL and OPG appeared to influence breast volume with a mean increase by 32 mL (P = 0.04) and a mean reduction by 27 mL (P = 0.04), respectively. Linking the RANKL/RANK/OPG pathway with breast volume changes supports further studies aiming at analysing breast changes during pregnancy with regard to breast cancer risk.},
author = {Wunderle, Marius and Rübner, Matthias and Häberle, Lothar and Schwenke, Eva and Hack, Carolin and Bayer, Christian M. and Koch, Martin and Schwitulla, Judith and Schulz-Wendtland, Rüdiger and Kozieradzki, Ivona and Lux, Michael P. and Beckmann, Matthias and Jud, Sebastian and Penninger, Josef M. and Schneider, Michael and Fasching, Peter},
doi = {10.1038/s41598-020-62070-3},
faupublication = {yes},
journal = {Scientific Reports},
note = {CRIS-Team Scopus Importer:2020-03-31},
pages = {5171-},
peerreviewed = {Yes},
title = {{RANKL} and {OPG} and their influence on breast volume changes during pregnancy in healthy women},
volume = {10},
year = {2020}
}
@article{faucris.204853569,
abstract = {Over the last two decades genetic testing for mutations in BRCA1 and BRCA2 has become standard of care for women and men who are at familial risk for breast or ovarian cancer. Currently, genetic testing more often also includes so-called panel genes, which are assumed to be moderate-risk genes for breast cancer. Recently, new large-scale studies provided more information about the risk estimation of those genes. The utilization of information on panel genes with regard to their association with the individual breast cancer risk might become part of future clinical practice. Furthermore, large efforts have been made to understand the influence of common genetic variants with a low impact on breast cancer risk. For this purpose, almost 450 000 individuals have been genotyped for almost 500 000 genetic variants in the OncoArray project. Based on first results it can be assumed that - together with previously identified common variants - more than 170 breast cancer risk single nucleotide polymorphisms can explain up to 18% of familial breast cancer risk. The knowledge about genetic and non-genetic risk factors and its implementation in clinical practice could especially be of use for individualized prevention. This includes an individualized risk prediction as well as the individualized selection of screening methods regarding imaging and possible lifestyle interventions. The aim of this review is to summarize the most recent developments in this area and to provide an overview on breast cancer risk genes, risk prediction models and their utilization for the individual patient.},
author = {Wunderle, Marius and Olmes, Gregor and Nabieva, Naiba and Häberle, Lothar and Jud, Sebastian and Hein, Alexander and Rauh, Claudia and Hack, Carolin and Erber, Ramona and Ekici, Arif Bülent and Hoyer, Juliane and Vasileiou, Georgia and Kraus, Cornelia and Reis, André and Hartmann, Arndt and Schulz-Wendtland, Rüdiger and Lux, Michael P. and Beckmann, Matthias and Fasching, Peter},
doi = {10.1055/a-0603-4350},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
note = {EVALuna2:34612},
pages = {481-492},
peerreviewed = {Yes},
title = {{Risk}, {Prediction} and {Prevention} of {Hereditary} {Breast} {Cancer} - {Large}-{Scale} {Genomic} {Studies} in {Times} of {Big} and {Smart} {Data}},
volume = {78},
year = {2018}
}
@article{faucris.211928783,
abstract = {INTRODUCTION: The care of patients with breast cancer is extremely complex and requires interdisciplinary care in certified facilities. These specialized facilities provide numerous services without being correspondingly remunerated. The question whether breast cancer surgery should be performed in an outpatient setting to reduce costs is increasingly being debated. This study compares inpatient surgical treatment with a model of the same surgery performed on an outpatient basis to examine the potential financial impact.
MATERIAL AND METHODS: A theoretical model was developed and the DRG fees for surgical interventions to treat primary breast cancer were calculated. A theoretical 1-day DRG was then calculated to permit comparisons with outpatient procedures. The costs of outpatient surgery were calculated based on the remuneration rates of the AOP (Outpatient Surgery) Contract and the EBM (Uniform Assessment Scale) and compared to the costs of the 1-day DRG.
RESULTS: The DRG fee for both breast-conserving surgery and mastectomy is higher than the fee paid in the context of the EBM system, although the same procedures were carried out in both systems. If a hospital were to carry out breast-conserving surgery as an outpatient procedure, the fee would be € 1313.81; depending on the type of surgery, the hospital would therefore only receive between 39.20% and 52.82% of the DRG fee. This was the case even for a 1-day treatment. Compared to the real DRG fees the difference would be even more striking.
CONCLUSION: Carrying out breast cancer surgery as an outpatient procedure would result in a significant shortfall of revenues. Additional services from certified centers, such as the interdisciplinary planning of treatment, psycho-oncological and social-medical care with the involvement of relatives, detailed documentation, etc., which are currently provided without surcharge or adequate remuneration, could no longer be maintained. The quality of processes and excellent results which have been achieved and ultimately the care given by certified facilities would be significantly at risk.},
author = {Formago, Margaret and Schrauder, Michael G. and Rauh, Claudia and Hack, Carolin and Jud, Sebastian and Hildebrandt, Thomas and Schulz-Wendtland, Rüdiger and Frentz, S. and Graubert, S. and Beckmann, Matthias and Lux, Michael P.},
doi = {10.1055/s-0043-114427},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
note = {EVALuna2:34710},
pages = {879-886},
peerreviewed = {Yes},
title = {{Should} {Breast} {Cancer} {Surgery} {Be} {Done} in an {Outpatient} {Setting}?: {Health} {Economics} {From} the {Perspective} of {Service} {Providers}},
volume = {77},
year = {2017}
}
@article{faucris.239913418,
author = {Goecke, Tamme W. and Jud, Sebastian and Weisbach, Volker Günter and Bender, A. W. and Schneider, Holm},
faupublication = {yes},
journal = {Geburtshilfe und Frauenheilkunde},
note = {CRIS-Team Scopus Importer:2020-07-01},
pages = {R3-R20},
peerreviewed = {Yes},
title = {{Stammzellen} aus {Nabelschnurblut} - ein besonderes {Gut}: {Informationen} für eine fachärztliche {Beratung} der {Schwangeren}},
volume = {70},
year = {2010}
}
@article{faucris.261673351,
author = {Preu, Caroline and Heindl, Felix and Jud, Sebastian and Hein, Alexander and Hack, Carolin and Beckmann, Matthias and Lux, Michael P. and Rauh, Claudia},
doi = {10.1055/a-0805-3978},
faupublication = {yes},
journal = {Klinikarzt},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {602-611},
peerreviewed = {unknown},
title = {{Standard} changing news der {Senologie} und der {Gynäkologischen} {Onkologie} 2018},
volume = {47},
year = {2018}
}
@article{faucris.234633913,
author = {Preuβ, Caroline and Hein, Alexander and Beckmann, Matthias and Jud, Sebastian},
doi = {10.1055/a-1067-2411},
faupublication = {yes},
journal = {Klinikarzt},
note = {CRIS-Team Scopus Importer:2020-02-21},
pages = {552-571},
peerreviewed = {unknown},
title = {{Standard} changing news der {Senologie} und der {Gynäkologischen} {Onkologie} 2019: {Neue} {Arzneimittelzulassungen} und {Änderungen} bestehender {Therapiekonzepte}},
volume = {48},
year = {2019}
}
@article{faucris.246694794,
author = {Preuβ, Caroline and Hein, Alexander and Beckmann, Matthias and Jud, Sebastian},
doi = {10.1055/a-1298-3661},
faupublication = {yes},
journal = {Klinikarzt},
note = {CRIS-Team Scopus Importer:2020-12-11},
pages = {468-482},
peerreviewed = {unknown},
title = {{Standard} {Changing} {News} der {Senologie} und der {Gynäkologischen} {Onkologie} 2020},
volume = {49},
year = {2020}
}
@article{faucris.261673600,
author = {Rauh, Claudia and Jud, Sebastian and Hein, Alexander and Hack, Carolin and Fasching, Peter and Beckmann, Matthias and Lux, Michael P.},
doi = {10.1055/s-0043-122593},
faupublication = {yes},
journal = {Klinikarzt},
note = {CRIS-Team Scopus Importer:2021-07-19},
pages = {648-654},
peerreviewed = {unknown},
title = {{Standard} {Changing} {News} der {Senologie} und {Gynäkologischen} {Onkologie}},
volume = {46},
year = {2017}
}
@article{faucris.116601804,
abstract = {We evaluated whether a 76-locus polygenic risk score (PRS) and Breast Imaging Reporting and Data System (BI-RADS) breast density were independent risk factors within three studies (1643 case patients, 2397 control patients) using logistic regression models. We incorporated the PRS odds ratio (OR) into the Breast Cancer Surveillance Consortium (BCSC) risk-prediction model while accounting for its attributable risk and compared five-year absolute risk predictions between models using area under the curve (AUC) statistics. All statistical tests were two-sided. BI-RADS density and PRS were independent risk factors across all three studies (P interaction = .23). Relative to those with scattered fibroglandular densities and average PRS (2(nd) quartile), women with extreme density and highest quartile PRS had 2.7-fold (95% confidence interval [CI] = 1.74 to 4.12) increased risk, while those with low density and PRS had reduced risk (OR = 0.30, 95% CI = 0.18 to 0.51). PRS added independent information (P < .001) to the BCSC model and improved discriminatory accuracy from AUC = 0.66 to AUC = 0.69. Although the BCSC-PRS model was well calibrated in case-control data, independent cohort data are needed to test calibration in the general population.},
author = {Vachon, Celine M. and Pankratz, V. Shane and Scott, Christopher G. and Häberle, Lothar and Ziv, Elad and Jensen, Matthew R. and Brandt, Kathleen R. and Whaley, Dana H. and Olson, Janet E. and Heusinger, Katharina and Hack, Carolin and Jud, Sebastian and Beckmann, Matthias and Schulz-Wendtland, Rüdiger and Tice, Jeffrey A. and Norman, Aaron D. and Cunningham, Julie M. and Purrington, Kristen S. and Easton, Douglas F. and Sellers, Thomas A. and Kerlikowske, Karla and Fasching, Peter and Couch, Fergus J.},
doi = {10.1093/jnci/dju397},
faupublication = {yes},
journal = {Journal of the National Cancer Institute},
note = {EVALuna2:14513},
peerreviewed = {Yes},
title = {{The} contributions of breast density and common genetic variation to breast cancer risk},
volume = {107},
year = {2015}
}
@article{faucris.204930568,
abstract = {Two-thirds of all breast cancer patients with metastases have a hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative subtype. Endocrine therapy is the treatment of choice in these patients since in addition to its effectiveness it can also maintain the patients' quality of life over a longer term. However, 44-62% of postmenopausal patients with metastatic breast carcinoma have primary tamoxifen resistance. After 3-5 years, 30-40% of the patients receiving tamoxifen treatment develop secondary resistance. Understanding the way in which resistance develops is therefore essential for developing treatment approaches that can prevent or reverse endocrine resistance. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays a central role here. As a result of the numerous interactions involved, complex issues arise that need to be taken into account in the development and use of therapeutic agents. In addition, this signaling pathway is the one that most frequently undergoes mutations in breast cancer. The prognostic and predictive significance of individual mutations has not yet been fully explained, but it might provide a basis for patient selection in clinical studies. Initial research results on the use of PI3K inhibitors suggest that this may be a highly promising therapeutic approach, with an acceptable side effect profile.},
author = {Lux, Michael P. and Fasching, Peter and Schrauder, Michael G. and Hein, Alexander and Jud, Sebastian and Rauh, Claudia and Beckmann, Matthias},
doi = {10.1159/000453133},
faupublication = {yes},
journal = {Breast Care},
note = {EVALuna2:33003},
pages = {398-404},
peerreviewed = {Yes},
title = {{The} {PI3K} {Pathway}: {Background} and {Treatment} {Approaches}},
volume = {11},
year = {2016}
}
@article{faucris.206596244,
abstract = {Background: Despite advancements in the treatment of primary and metastatic breast cancer, many patients lack a durable response to these treatments. Patients with triplenegative breast cancer (TNBC) and human epidermal growth factor receptor 2(HER2)-positive breast cancer who do not have a pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) have a very poor prognosis. Tumor-infiltrating lymphocytes (TILs) have been identified as a predictive marker for pCR after NACT in TNBC and HER2-positive breast cancer. These patient populations could also be suitable for novel treatment strategies including neoepitope-based therapies. This work analyses the effect of TILs on the pCR in neoadjuvantly treated patients in the TILGen study and presents the procedures aimed at establishing neoepitope-based therapies in this study. Methods: Neoadjuvantly treated HER2positive and TNBC patients were eligible for the presented analysis concerning the association between TILs and pCR. A total of 146 patients could be identified within the TILGen study. TILs were evaluated as percentage of stromal tumor tissue in core biopsies at primary diagnosis. The phenotype 'lymphocyte-predominant breast cancer' (LPBC) was associated with pCR by logistic regression adjusted for estrogen receptor status, progesterone receptor status, HER2 status, age at diagnosis, and grading. Results: LPBC was seen in 24 (16.4%) patients. In this patient group, 66.7% achieved a pCR, while the pCR rate was 32.8% in patients with a low TIL count. The adjusted odds ratio was 6.60 (95% confidence interval 2.02-21.56; p < 0.01). Conclusion: TILs are a strong predictor of pCR in TNBC and HER2-positive breast cancer patients. Implications for the use of this information including the effect on prognosis might help to identify patients most likely to benefit from a neoepitope-based therapy approach. (C) 2018 S. Karger GmbH, Freiburg},
author = {Würfel, Franziska and Erber, Ramona and Hübner, Hanna and Hein, Alexander and Lux, Michael P. and Jud, Sebastian and Kremer, Anita and Kranich, Hannah and Mackensen, Andreas and Häberle, Lothar and Hack, Carolin and Rauh, Claudia and Wunderle, Marius and Gaß, Paul and Rabizadeh, Shahrooz and Brandl, Anna-Lisa and Langemann, Hanna and Volz, Bernhard and Nabieva, Naiba and Schulz-Wendtland, Rüdiger and Dudziak, Diana and Beckmann, Matthias and Hartmann, Arndt and Fasching, Peter and Rübner, Matthias},
doi = {10.1159/000486949},
faupublication = {yes},
journal = {Breast Care},
note = {EVALuna2:34061},
pages = {8-14},
peerreviewed = {Yes},
title = {{TILGen}: {A} {Program} to {Investigate} {Immune} {Targets} in {Breast} {Cancer} {Patients} - {First} {Results} on the {Influence} of {Tumor}-{Infiltrating} {Lymphocytes}},
volume = {13},
year = {2018}
}
@article{faucris.306488116,
abstract = {Background: Despite advancements in the treatment of primary and metastatic breast cancer, many patients lack a durable response to these treatments. Patients with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2(HER2)-positive breast cancer who do not have a pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) have a very poor prognosis. Tumor-infiltrating lymphocytes (TILs) have been identified as a predictive marker for pCR after NACT in TNBC and HER2-positive breast cancer. These patient populations could also be suitable for novel treatment strategies including neoepitope-based therapies. This work analyses the effect of TILs on the pCR in neoadjuvantly treated patients in the TILGen study and presents the procedures aimed at establishing neoepitope-based therapies in this study. Methods: Neoadjuvantly treated HER2-positive and TNBC patients were eligible for the presented analysis concerning the association between TILs and pCR. A total of 146 patients could be identified within the TILGen study. TILs were evaluated as percentage of stromal tumor tissue in core biopsies at primary diagnosis. The phenotype ‘lymphocyte-predominant breast cancer' (LPBC) was associated with pCR by logistic regression adjusted for estrogen receptor status, progesterone receptor status, HER2 status, age at diagnosis, and grading. Results: LPBC was seen in 24 (16.4%) patients. In this patient group, 66.7% achieved a pCR, while the pCR rate was 32.8% in patients with a low TIL count. The adjusted odds ratio was 6.60 (95% confidence interval 2.02-21.56; p < 0.01). Conclusion: TILs are a strong predictor of pCR in TNBC and HER2-positive breast cancer patients. Implications for the use of this information including the effect on prognosis might help to identify patients most likely to benefit from a neoepitope-based therapy approach.
Tumors in radiologically dense breast were overlooked on mammograms more often than tumors in low-density breasts. A fast reproducible and automated method of assessing percentage mammographic density (PMD) would be desirable to support decisions whether ultrasonography should be provided for women in addition to mammography in diagnostic mammography units. PMD assessment has still not been included in clinical routine work, as there are issues of interobserver variability and the procedure is quite time consuming. This study investigated whether fully automatically generated texture features of mammograms can replace time-consuming semi-automatic PMD assessment to predict a patient's risk of having an invasive breast tumor that is visible on ultrasound but masked on mammography (mammography failure).
This observational study included 1334 women with invasive breast cancer treated at a hospital-based diagnostic mammography unit. Ultrasound was available for the entire cohort as part of routine diagnosis. Computer-based threshold PMD assessments ("observed PMD") were carried out and 363 texture features were obtained from each mammogram. Several variable selection and regression techniques (univariate selection, lasso, boosting, random forest) were applied to predict PMD from the texture features. The predicted PMD values were each used as new predictor for masking in logistic regression models together with clinical predictors. These four logistic regression models with predicted PMD were compared among themselves and with a logistic regression model with observed PMD. The most accurate masking prediction was determined by cross-validation.
About 120 of the 363 texture features were selected for predicting PMD. Density predictions with boosting were the best substitute for observed PMD to predict masking. Overall, the corresponding logistic regression model performed better (cross-validated AUC, 0.747) than one without mammographic density (0.734), but less well than the one with the observed PMD (0.753). However, in patients with an assigned mammography failure risk >10%, covering about half of all masked tumors, the boosting-based model performed at least as accurately as the original PMD model.
Automatically generated texture features can replace semi-automatically determined PMD in a prediction model for mammography failure, such that more than 50% of masked tumors could be discovered.
}, author = {Haeberle, Lothar and Hack, Carolin and Heusinger, Katharina and Wagner, Florian and Jud, Sebastian and Uder, Michael and Beckmann, Matthias and Schulz-Wendtland, Rüdiger and Wittenberg, Thomas and Fasching, Peter}, doi = {10.1186/s40001-017-0270-0}, faupublication = {yes}, journal = {European Journal of Medical Research}, keywords = {Mammographic density; Mammography screening; Masking; Risk prediction; Sensitivity; Texture analysis; Variable selection}, note = {UnivIS-Import:2017-12-18:Pub.2017.tech.IMMD.IMMD9.usinga}, peerreviewed = {Yes}, title = {{Using} automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound}, url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577694/}, volume = {22}, year = {2017} } @article{faucris.208554674, abstract = {Background: In women with early breast cancer, a pathological complete response (pCR) after neoadjuvant chemotherapy is reported to be associated with an improvement of the survival. The aim of this survey among physicians was to investigate whether the probability of achieving pCR in patients with a hormone receptor-positive, HER2-negative disease encourages physicians to recommend neoadjuvant chemotherapy. Methods: The study was conducted via an online survey that was sent to 493 physicians, who were either known as members of national guideline committees, heads of breast cancer centers, being high recruiters in clinical trials or leading a private practice. Participants were asked about a specific case that should resemble patients for whom it is unclear, whether they should be treated with chemotherapy. Results: 113 (24.5%) physicians participated at the survey, out of which 96.5% had a work experience of more than 10 years and 94.7% were board certified in their specialty. A total of 84.1% would consider pCR for a decision concerning neoadjuvant chemotherapy. With regard to the pCR probability, 2.7 and 10.6% of the participants demanded at least a pCR rate of 5 and 10%, respectively, while 25.7% were satisfied with 20% probability, and another 25.7% with a pCR rate of 30%. Conclusions: The vast majority of the long-term experienced physicians would embrace the implementation of a further method such as the prediction of pCR probability in clinical routine to support decision making regarding the necessity of neoadjuvant chemotherapy. The cut-off of around 30% pCR probability seems to be a realizable rate to distinguish patient groups. }, author = {Gaß, Paul and Untch, Michael and Mueller, Volkmar and Moebus, Volker and Thomssen, Christoph and Häberle, Lothar and Erber, Ramona and Hein, Alexander and Jud, Sebastian and Lux, Michael P. and Hack, Carolin and Hartmann, Arndt and Kolberg, Hans-Christian and Ettl, Johannes and Lueftner, Diana and Jackisch, Christian and Beckmann, Matthias and Janni, Wolfgang and Schneeweiss, Andreas and Fasching, Peter and Nabieva, Naiba}, doi = {10.1055/a-0642-9462}, faupublication = {yes}, journal = {Geburtshilfe und Frauenheilkunde}, note = {EVALuna2:34856}, pages = {707-714}, peerreviewed = {Yes}, title = {{Using} {Probability} for {Pathological} {Complete} {Response} ({pCR}) as a {Decision} {Support} {Marker} for {Neoadjuvant} {Chemotherapy} in {HER2} {Negative} {Breast} {Cancer} {Patients} - a {Survey} {Among} {Physicians}}, volume = {78}, year = {2018} }